OREGON STATE UNIVERSITY
COLLEGE OF PHARMACY
ACADEMIC REPORT FOR 2006-2007
1. 2006-2007 Highlights
Preface
As described in last year’s report, the professional doctor of pharmacy (Pharm. D.) program was granted continuing accreditation by the Accreditation Council of Pharmacy Education (ACPE) in January 2006. While the accreditation report was complimentary of the Pharm. D. program as a whole, a focused on-site evaluation visit is scheduled for November 5 and 6, 2007 to assess progress on several specific areas of concern. During the past year, we have spent considerable effort addressing the issues of greatest importance as described below.
The foremost concern cited by ACPE was the college’s long-standing history of inadequate financial resources that had improved only marginally since 1999. At the start of the 2005-2006 fiscal year, the college’s E&G budget was approximately 30% below peer colleges/schools of pharmacy with equal student size, translating into a smaller than desired faculty size and faculty salaries that were markedly below market value (approximately 25th percentile of peers.)
Subsequently, a three year financial plan to significantly raise student tuition was developed and approved by the Provost and the Vice President for Finance with the first phase implemented in fall 2006. As a consequence, professional student tuition rose by $2,500 per year in fall of 2006 and will increase by an additional $1,000 per year in fall of 2007. A third increase of $1,000 per year is planned for fall 2008, translating into an annual tuition when fully implemented of ~$15,000 for Oregon residents and ~$25,000 for non-residents (excluding other required university and college fees). Under this plan, all new revenues go directly to the college. With a total student head count of approximately 335 students, each $1,000 increase in tuition yields an additional $335,000 to the colleges operating budget. The number of students entering the professional program will also increase in 2007, estimated at this time to be approximately 90 first year students.
There have been three demonstrable outcomes of the new and anticipated future revenues. First, ten new faculty have been hired with two starting late in the 2005-2006 fiscal year (Chrissa Kioussi and Stacy Ramirez), six starting during the 2006-2007 fiscal year (Dan Hartung, Joel Marrs, Jessina McGregor, Kerry McPhail, Jeegisha Patel, and Craig Williams), and two others scheduled to start in fall of 2007 (Ganesh Cherala and Shannon Gerding). Four of these represent new lines; the others replace faculty who retired or resigned. Three additional faculty recruitments will be started during the 2007-2008 fiscal year with anticipated start dates in winter or summer of 2008. Unexpectedly, the Director of Advanced Experiential Education who is responsible for overseeing approximately 30% of the entire curriculum resigned in July 2007 (effective August 9, 2007). We are rapidly mounting the search to refill this critical faculty position. Second, permission was received from the Provost and Vice Provost for Academic Affairs to grant salary increases averaging 4% (range 2% to 10%) in September 2006 for those faculty most affected by salary compression or other inequities. When coupled with the previously scheduled merit pool of 4% for salary increases in January 2007, faculty salaries are near the 50th percentile of peers, though still several thousand dollars per year below starting salaries for recent graduates from the professional and graduate programs. Third, a move to the Center of Health and Healing on the OHSU campus in January 2007 remarkably enhanced the work and learning environment for our Portland based faculty and students, but at a cost of nearly $250,000 per year more in lease fees. Because some of the new expenses for faculty (including start up packages) and leases fees are out of sequence with the phase in of new revenue, we experienced a decline in financial reserves during the 2006-2007 fiscal year, but should not experience further declines in the 2007-2008 fiscal year.
a. Programmatic achievements
▪ Initiatives in support of student engagement and success
Professional Program
The College Curriculum Committee meets frequently throughout the year with a commitment to continuous quality improvement and assuring academic excellence of the professional program. During the past year, this committee paid particular attention to improving articulation of the curriculum across the two campuses and responding to comments received during the accreditation process. Among the notable achievements for this year are:
• Designated anatomy and physiology as pre-pharmacy requirements for students entering the professional program in 2008. When this transition is fully implemented, nearly the entire professional curriculum will be taught by College of Pharmacy faculty and preceptors. It is also anticipated that the percentage of students entering the college with a prior baccalaureate degree will approach 100%; the percentage of post-BS new student for fall 2007 is already exceeds 70%. Most importantly, removing these courses from the professional curriculum will allow gradual re-organization of the professional curriculum to balance the degree of difficulty across the first three academic years, possibly integrating some of therapeutic topics traditionally taught in the third year into the medicinal chemistry/ pharmacology series, and exploring a mechanism to introduce electives into the curriculum.
• Shifting the focus of the fall quarter first professional year clinical applications course to professionalism.
• Moving the Foundations of Drug Action Course to fall quarter of the first professional year. This is the first step in allowing a shift of some of the second year medicinal chemistry/ pharmacology series into the first year, then bringing therapeutic topics into the second professional year. As indicated above, it is envisioned that there will be better integration/ articulation of therapeutics with medicinal chemistry/pharmacology over time.
• Re-organizing the Health Care Systems courses in the first year with the important addition of including faculty from Public Health (College of Health and Human Science) as part of the instructional team. Not only does this recognize the important linkage between the two colleges, but also has fostered at least one new research/ practice affiliation between faculty from the two colleges.
• Revising the Pharmaceutics Course series in the first professional year to include greater instruction in drug compounding, an area of increasing interest within the practice community.
• Extensively updating the Community and Institutional introductory pharmacy professional experience course syllabus (Phar 710/711) to incorporate explicit learning objectives and a mechanism for students to petition for a waiver of the course in lieu of obtaining equivalent professional experience. The new syllabus closely models cooperative education curricula and clearly describes how students must obtain approval of practice sites, instructions for developing a portfolio documenting achievement of learning objectives, and standardized interim and end of experience assessment of both student achievement and preceptor performance. A petition was submitted to ACPE to obtain permission to institute this novel, yet very effective learning format.
Experiential education (designated by ACPE as “introductory and advanced pharmacy practice experience” programs) is a critical portion of the College of Pharmacy Curriculum, comprising nearly 30% of the academic credits including the entire fourth professional year. The leadership team for this component of the curriculum has consisted of the Director of Advanced Experiential Education (located in Portland), the Early Experiential Coordinator (located in Corvallis), and a 1.0 FTE administrative program specialist in Portland. We faced a significant challenge during the last academic year following the resignation of the Early Experiential coordinator in July 2006. Attempts to fill the position were unsuccessful, though we were able to conduct the program thanks to the joint efforts of assistant dean Gary DeLander, the Director of Advanced experiential programs (Deanna Moretz), and a part time appointment of Dr. Anne DeLander to teach the clinical applications course. In face of adversity, this group is to be congratulated for initiating the changes in Phar 710/711 as described in the preceding paragraph. Dr. Moretz has also served as part of an emerging “Northwest Consortium” of colleges of pharmacy including OSU, the new college at Pacific University, the University of Washington, Washington State University, Idaho State University, and the University of Montana. Among the outcomes of this collaboration is greater standardization of calendars for placing students and consistent assessment tools so that practitioners with students from multiple institutions do not have to have multiple formats to follow. More detail on the challenges for the pharmacy practice experience program and plans for future collaboration are found in the section on goals for 2007-2008.
Assessment of the curriculum, student success, and competence of graduates is increasingly emphasized by ACPE and university. The College of Pharmacy Assessment Committee continues to expand the scope of its activities and improving the information flow to the curriculum committee to better inform the process of curricular revision.
For several years, a standardized “curricular survey” has been administered at the end of each academic year, whereby students self-assess their attainment of the academic outcomes and competencies established by the curriculum committee. This information is used by both the assessment and curriculum committees to track progression of longitudinal learning over the four years for a given cohort of students and also to compare results across time for each of the professional years. Areas of possible deficiency are addressed by proposing curricular revision; changes over the ensuing years indicate the success of the curricular changes in improving performance. Results of these surveys can be provided upon request.
Similarly, the American Association of Colleges of Pharmacy (AACP) is developing standardized assessment tools that can be used for peer comparisons with other colleges and schools of pharmacy. In 2007, we used the AACP graduating student assessment instrument for the first time. Results for OSU graduates are found in Appendix A, but the peer comparisons have not been received at the time of this writing. Future plans call for using the preceptor assessment forms and surveying past graduates on a periodic basis (e.g., every five years.)
The College has also conducted a college specific “learning environment” survey for several years to assist with assessment and provide support for the Diversity Committee (See appendix B). Sections of the Learning Environment survey include: Curriculum, Instructional Resources and Technology, College Support and Environment, Overall Experience, Demographic Data, and Orientation. Results from each section are shared with faculty, committees and administrators to consider as they implement changes for the upcoming year. Results from learning environment surveys over time show if changes have resulted in measurable outcomes. For example, the Learning Environment Survey from spring 2006 indicated dissatisfaction with the physical facilities and overall learning environment during the P3 year. The move to the new building in Portland (described below) led to significant improvements in the students’ level of satisfaction during the 2007 surveys
The move of the Portland based Pharmacy Practice faculty and P3 student teaching programs to the new Center for Health and Healing building at OHSU has been an outstanding morale booster for the faculty, staff, and students. The new classroom and practice laboratory are not only much more esthetically pleasing than the previous facilities, but having the faculty easily accessible to the students throughout the day has markedly increased professional and social interaction. We have also implemented several changes to enhance student experience on both the Corvallis and Portland campuses and to be more responsive to students with academic needs. Among changes that we were implemented during the 2006-20007 academic year are:
• Faculty notify the head advisor when students score a C- or lower on a midterm examination. The head advisor then invites the student to meet with her to discuss possible causes and remediation.
• Increased collaboration with faculty to assist students with personal situations that are interfering with academic performance or health.
• To assist students in the transition from the second professional year in Corvallis to the third professional year in Portland, a formalized orientation program has been developed that is divided into a segment presented during the P2 year and another that precedes the start of the P3 year.
• The department chair in Portland meets with the P3 year student class leaders several times each quarter to identify and address student concerns.
• One of the college advisors now comes to the Portland campus 2-3 times each month. P3 and P4 students are notified ahead of time which days an advisor will be on campus. Students in academic trouble are individually notified.
• The Director of Experiential programs has expanded the orientation program for the students preparing to enter the fourth professional year. We have also introduced quarterly “P4” reunion days when all of the fourth professional year students are invited back to campus for a combination of professional programming and social events. Prior to graduation, a convocation is held to provide a law update and prep course for the licensing examination and also to conduct end of program assessments.
A growing shortage of pharmacists translates into high demand for our graduates and excellent starting salaries. As a consequence, the number of undergraduate students at OSU declaring a pre-pharmacy intent has escalated to over 500 students. This has placed an unprecedented demand on access to a variety of biological sciences and chemistry courses in the College of Science and stressed the advising offices in both the College of Pharmacy and the College of Science. One advisor and one 0.5 FTE College Student Services Administration (CSSA) intern employed by the college attempt to advise all of the pre-pharmacy students. We also engaged a second CSSA intern during spring quarter to assist with several students services office projects. One outcome was creation of a manual entitled “How to get any job with a General Science Degree” program.
The College of Pharmacy is committed to providing a welcoming atmosphere for its students and staff, promoting professionalism, and ensuring student success. Numerous events are scheduled throughout the year to bring students, faculty, and in some cases, alumni, together and to continually instill a spirit of collegiality and professionalism. Many of the events listed below were identified in reports from prior years. Those marked with an asterisk (*) are new for 2006-2007.
• A three day orientation program for incoming students before the start of fall quarter.
• *(An orientation program for second professional year students will be added for 2007- 08)
• *A two-day orientation program in Portland for third year professional students (expanded form one year). Also addition of a welcoming barbeque.
• *An expanded orientation program in Portland for students preparing to enter the fourth professional year Advanced Pharmacy Practice Experiential program
• *Addition of three P4 “reunion days” throughout the year to improve communications and class spirit.
• The White Coat Ceremony in the fall for incoming students
• An all college luau and pig roast in the in the fall
• The Benefactor’s Reception in the fall for scholarship recipients to meet their donors
• The Homecoming Brunch
• The Apothecary Ball
• Icons’ of Pharmacy Dinner
• The student recognition banquet and talent show in the spring
• The College of Pharmacy graduation recognition ceremony
Graduate Program review
Under the leadership of Associate Professor Theresa Filtz, Chair of the Graduate Studies Committee, faculty in the college conducted an in-depth self-study of our graduate programs in preparation for a formal review by the Graduate Council that occurred in June of this year. The last time the graduate programs were formally reviewed was in 1994. A full copy of the self-study is available upon request. We are still awaiting the final report from the graduate council, but we received favorable comments from the external reviewers during the site visit. A few highlights are noted below.
The pharmacy graduate programs have maintained enrollments of 23-35 students per year over the past 10 years. However, the investment by the College in graduate education has increased significantly from 2 graduate teaching assistant (GTA) slots in 1994 to 7.5 GTA slots with full, nationally competitive stipends in 2006-07.
Graduate student quality is high with an average incoming student GPA of 3.44 and GRE scores in the top 25% to 40% of test takers. Of particular note, one of our current graduate students was just awarded one of OSU’s highest graduate student competitive honors in the form of the P.F. and Nellie Buck Yerex fellowship. Previous students have won competitive fellowships for stipend support from the American Council for Pharmaceutical Education. Our retention and successful graduation rate over the past ten years is a solid 80%.
Efforts at recruitment of domestic students have been bolstered by prioritizing the award of first year GTAs to domestic students, resulting in an increase in domestic students in the program from 15% in 1994 to 42% in 2007. Increased efforts to recruit students from Oregon and the Pacific Northwest through College support of summer undergraduate research experiences and recruiting visits to regional universities and Colleges have netted at least one regional student each year for the past several years.
Graduate students in Pharmacy at OSU can choose among three primary disciplinary pathways, medicinal chemistry/natural products, pharmacology, and pharmaceutics. We have also created an option within the Pharm. D. program for students to pursue a combined Pharm. D/Ph. D degree. Two students are currently enrolled in this pathway. While programs of study in Pharmacy focus within disciplinary bounds, cross-disciplinary collaborations have increased in the past several years as reflected in joint faculty grant and manuscript submissions. Cross-disciplinary graduate student socialization has also improved.
A significant outcome of the self-study and preparation for the review was the development of a graduate student handbook (available on the College of Pharmacy website) that clearly articulates coursework and academic requirements; program committee creation and responsibilities; oral and written preliminary examination requirements; research proposal development; final examination and thesis requirements; as well as guidance for life as a gradate student, professionalism and ethics.
Graduate students and alumni are very satisfied with the overall program judging from recently administered surveys. Most importantly, alumni report employment related to their graduate degrees and satisfaction that the graduate program met their career goals. A perusal of post-graduation employment shows that our students return to academic professorships, obtain postdoctoral positions at high quality universities, or obtain employment in large and small pharmaceutical firms.
Overall, we believe that we deliver a high quality graduate program providing training in cutting-edge research techniques that our graduates find to be valuable. As with most other programs at OSU, we faced challenges with replacing productive faculty who retired or were recruited elsewhere. The College made concerted efforts this year to improve faculty salaries which had fallen well below the 50th percentile for national peers but which are now at or close to national averages. The youth of our current faculty and the significant ongoing investment of the College in its faculty, its research mission and graduate student support bode well for the future.
▪ Major research/scholarship initiatives
During the 2006-07 fiscal year, College of Pharmacy faculty received 25 new and renewal grants and contracts totaling $2,149,978, as reported by the grants and contracts office. However, the college accounting office recorded 29 new and renewal grants and contracts totaling $2, 667,105. We are investigating the reason for difference in reported values. In any event, this represents a marked jump in revenues after a decline following departure of a highly productive faculty member two years ago. We anticipate a steady growth in research funding over the next biennium as newly hired junior faculty reach full productivity. Our goal is to reach $3 million in extramural funding by the end of the next biennium.
According to the May 11, 2007 report from the Office to Technology Transfer, 52 invention disclosures and 70 patent applications were filed by faculty at Oregon State University. Nine of the invention disclosures and 11 patent applications were generated by faculty in the college of pharmacy (second only to the College of Engineering.) Importantly, total patent and royalty income generated by the College of Pharmacy faculty for the university since 1981 is over $10.7 million, including over $1.8 million to the college of pharmacy. In 2006-2007 over $67,000 came to the College of Pharmacy in royalty income from four active patented technologies.
See Appendix C: Grants and Contracts (listed alphabetically by faculty PI)
See Appendix D: Publications, Presentations, Professional and Public Service by
Faculty (listed alphabetically by faculty last name)
Listed below is an updated summary of the research initiatives within the college of pharmacy. These initiatives remain fundamentally unchanged from the last two years’ reports and are directly aligned with the strategic plans of the university, the college, and the two college departments. Specifically they address the OSU thematic area of realizing fundamental contributions in the life sciences and optimizing the health and well-being of the public. All new professorial rank faculty hired in the last year or being recruited are targeted to participate in these research focus areas.
The most significant achievement during the past few months is funding of the Oregon Translational Research and Drug Discovery Initiative (OTRADI) by the state legislature. Total funding is $5.1 million for the biennium to establish the infrastructure for this important economic development engine. A portion of the funding, still to be determined, will be used to support the antibiotics drug discovery activities from the Colleges of Pharmacy, Veterinary Medicine, and Science. This complements and expands similar efforts funded internally by the College for the past 1.5 years.
▪ Areas of research focus
• The multidisciplinary, translational infectious diseases research program continues to mature with collaborations between the Departments of Pharmaceutical Sciences and Pharmacy Practice and the Colleges of Pharmacy, Veterinary Medicine, and Science. The emphasis on the Corvallis campus is on the discovery of novel naturally occurring and semi-synthetic antibacterial molecules. Complementary investigations in the College of Pharmacy are examining the creation of new vaccines and novel modes of vaccine delivery. An OSU research team spearheaded by Luiz Bermudez (Veterinary Medicine) and Mark Zabriskie (Pharmaceutical Sciences) participated in development of a statewide signature research center proposal to the Oregon Innovation Council (Oregon InC) that ultimately was funded by the state legislature as the Oregon Translational Research and Drug Discovery Initiative (OTRADI), described above. This is a joint proposal by Oregon Health & Science University (OHSU), Oregon State University (OSU), Portland State University (PSU), University of Oregon, and several Oregon-based biotechnology companies. The institute will focus on the development and commercialization of therapeutics, vaccines, and diagnostics for infectious diseases, neurodegenerative disorders, cancer and other major problems affecting human health. A primary objective of this proposal is to create a unique drug development consortium and facility that will bridge the gaps between basic research, development and commercialization.
• A complementary component of the translational infectious diseases research program is conducted by faculty on the Portland campus who conduct research to identify mechanisms of antibiotic resistance, test novel dosing models in humans, and perform pharmacoeconomic/cost effectiveness analysis of marketed antibiotics. Current work includes studies of bacterial resistance to fluoroquinolones, in various organisms, including Staphylococcus aureus, Pseudomonas aeruginosa, and Streptococcus pneumoniae. This research includes collaborations with Corvallis faculty and OHSU’s Molecular Medicine Institute. In addition, pharmacokinetic modeling of various antimicrobials in special populations is studied as well as assessment of pharmacists’ involvement in vaccine preventable diseases.
• A focus of the pharmacology section of the Department of Pharmaceutical Sciences is to refine and expand our understanding of cell signaling as it pertains to activation of cellular processing and control of gene expression. Development of genetically modified small rodent models that facilitate our understanding of the significance of alterations in organisms is an emphasis of these studies. Investigations include a range of therapeutic concerns from ischemic diseases, cardiovascular function and cancer. Small rodent models of disease currently available are targeted toward mechanisms involved in for melanoma, leukemia and fetal development.
• Cardiovascular disease pharmacotherapy. Current activity in this group includes clinical trials and pharmacokinetic, pharmacodynamics, metabolic, and pharmacoeconomic/cost effectiveness studies of new and existing lipid lowering drugs. Novel patient programs for improving patient care in patients with lipid disorders and congestive heart failure are evaluated. Collaborative efforts have been initiated with the OHSU cardiovascular division and Heart Research Center. The hiring of several new faculty who joined the group in summer and fall of 2006 has expanded the research to include hypertension, heart failure and other chronic cardiovascular diseases.
• Pharmaceutics faculty examine metabolic processes and mechanisms of drug disposition that influence the therapeutic utility of drugs. Investigations explore genomic influences on drug metabolism and how this may alter pharmacokinetic models and drug toxicity.
• Faculty on the Portland campus are developing a pharmacokinetics/ pharmacodynamics modeling and consulting program as a component of the OHSU School of Medicine’s Pharmacokinetics Core. Areas of research are in infectious diseases, nephrology, and oncology. The activity of this group will be enhanced in the coming year by the addition of a new faculty member (Dr. Ganesh Cherela) in October 2007.
• The Drug Use Research and Management (DURM) Program has extended their contract with the Oregon State Medical Assistance Program and Care Oregon to help shape state policies for the cost-effective use of medications for low-income families. Their research evaluates policies and methods to improve the use of prescription drugs. This program is described further on page 10 of the report as part of the “major outreach and engagement activities” section.
• Pharmacoeconomics and biostatistics. These faculty conduct economic evaluations of pharmaceutical and other therapies, assess practice patterns and subsequent outcomes, and use large data bases (such as medical claims data bases) to develop and test hypotheses about occurrence of disease and treatment patterns. Clinical areas include oncology (brain tumors and chemoprotective agents), cardiology, diabetes, neurology, osteoporosis, and women’s health. Progress in this research area will expand in 2007-2008 with the addition of a new pharmacoeconomics specialist, Dr. Dan Hartung and pharmacoepidemiology specialist, Jessina McGregor.
• The EMPOWER diabetes management demonstration and research project was launched in 2006 in partnership with the directors of the human resource departments from the cities of Eugene and Springfield and Lane County. This program is designed to assess the impact of the community pharmacist’s education of patients on diabetes control and healthcare utilization. During the 2006-2007 we added the Bethel School District in Springfield and the City of Corvallis as participating employers and will soon be completing the contracts with the City of Salem and the SAIF Corporation. Preliminary assessment of the first 60 patients from Lane County indicates improved clinical outcomes in the patients served. Further description of the EMPOWER project are found on page 11 of this report as part of the “major outreach and engagement activities” section.
▪ Major outreach/engagement initiatives
New activities during the past year are:
• The College of Pharmacy welcomed Stan Hull, Senior Vice President with the U.S. Pharmaceuticals Division of GlaxoSmithKline (GSK) as “Dean for a Day” in February. The Dean for a Day event was inspired when long time college supporter Vince Whiting from GSK purchased the Dean for a Day silent auction item during the Oregon State Pharmacy Association annual meeting and invited Mr. Hull to be his surrogate dean. Hull, Whiting, and other representatives from GSK spent two days visiting the college, meeting with faculty and having lunch with Provost Randhawa and Vice President Cassidy. Several opportunities for future research and professional collaborations with GSK were identified.
• The Second Annual “Icons of Pharmacy” dinner to honor new inductees into the College of Pharmacy “Hall of Fame” was held in May.
• On February 21, several pharmacists and over 50 student pharmacists from OSU participated in the Oregon State Pharmacy Association “Pharmacy Day” events at the state capital in Salem. Many of them were able to meet with the representatives and senators from their home community. They also assisted in a health fair that included administering flu vaccine as well as bone density, cholesterol, diabetes, and hypertension screenings for the legislators and their staffs. Their goal was to demonstrate to legislators that pharmacists are an important member of the interdisciplinary health care team.
• A large number of pre-pharmacy students, along with other pre-health majors collaborated with the American Association of Retired Persons (AARP) to conduct educational sessions for senior citizens about the new Medicare Part D prescription drug plans.
Numerous activities from the previous two years’ reports continue and are reproduced below with minor modifications.
• The student pharmacy association OSSP (Oregon State Student Pharmacists) conducts a variety of community outreach programs that include presentations on asthma, poison prevention, and substance abuse avoidance to elementary, middle school, and high school students; asthma, diabetes, and hypertension screening at pharmacies in the Corvallis and Portland areas; and collaborates with pharmacists across the state to provide flu shots in local pharmacies. The Phi Delta Chi fraternity partners with parish nurse organizations and OSU County Extension Agents in Corvallis, Medford, and Portland to provide brown bag medication reviews for senior citizens at local churches.
• For the past ten years, the College of Pharmacy has supported the administration of the state’s Medicaid program for low-income elderly, children, and disabled residents under the provisions of a statewide interagency agreement with the Department of Human Services (DHS), Office of Medical Assistance Programs (OMAP.) The resulting Drug Use Research and Management (DURM) program has enhanced the safety, effectiveness, and cost-efficiency of prescription drug use for Medicaid patients in Oregon. A secondary contract exists with Care Oregon, a health maintenance organization that serves Medicaid patients in the greater metropolitan Portland area. Responsibilities of the DURM team include administering the Oregon Drug Use Review (DUR) Board for DHS, evaluating drug utilization patterns among Oregon Health Plan (OHP) members, analyzing and making recommendations to DHS on drug use policies, and developing education strategies for Oregon Health Plan clinicians. Two additional prescriber education programs mandated by the state legislature are the Polypharmacy Review Program and the Plan Drug List (PDL) Education Initiative. In 2006-2007 the OMAP contract was renewed with administrative oversight transferred to the Office of Sponsored Programs in the Research Office and included adjustments to the facilities and administration charges. Gross revenues from this contact have grown steadily over the last several years and reaching approximately $900,000 annually in the 2007 fiscal year.
• A goal of the college’s strategic plan is to increase the visibility and service of the college to the pharmacists and citizens of the state. Accordingly, development of a center for innovative pharmacy practice and entrepreneurship is a major initiative in the college’s strategic plan and its capital campaign agenda. As an initial step, several members of the Department of Pharmacy Practice initiated a demonstration/ research project in cooperation with the human resource directors for the cities of Eugene and Springfield and Lane County. As described elsewhere in this report, the project has been expanded in 2007 to include the Bethel School District in Springfield and the City of Corvallis. Additional employers will be added in 2007-2008 including the City of Salem and SAIF Corporation. The primary goal of this research is to demonstrate the health related and economic impacts of a pharmacist-delivered patient empowerment program (education and medication therapy management) for diabetics. This project will assess the impact of waiver of co-pays for diabetes-related utilization with and without a pharmacist directed empowerment program. If this project is successful, it will be expanded to other parts of the state and provide pharmacists’ care for additional chronic health problems.
▪ National/International impact of programs and initiatives
Student’s International Activities
As part of the Pharm.D. program, the College of Pharmacy offers an elective practice experience which is designed to broaden the students knowledge about health care, pharmacy practice, and education specifically in another health care system (International Pharmacy). The students spend six weeks in one of the approved sites for the international program (Australia, New Zealand, or England). The practice varies depending on the specialty (hospital, community, industry, or government). Last year, four students took advantage of this opportunity and carried out their Advanced Practice Experience at international locations. Mike Fahey went to New Zealand, Eryn De La Cruz and Sami Swisher went to Australia, and Lacy Wright went to England. We are exploring a future exchange program with Khon Kaen University in Thailand.
Two students, Marie Dorsey and Jeff McCoy, traveled as pharmacy missionaries to Papua, Indonesia, for a summer internship through the Summer Medical Institute Northwest program at New Heights Clinic. Rowan Madix and Colleen Shipman joined class of 1964 alumnus Steve Roath at a medical mission in Guatemala.
International Students
Last year, only 21 international students out of 341 students were enrolled in the Pharm. D. program. The low international enrollment could be due to one or more factors, such as very competitive admission process, high tuition fees, language barrier, or the degree is not appreciated in their home countries due to healthcare system differences.
On the other hand, our graduate student body consists of 61% international students. Our graduate program has an excellent reputation among international applicants as indicated by the high overall number of international applications (about 85% of the total applications). As one of the leading universities located in the Pacific Rim, the majority of international applications were from Asian countries. Nevertheless, the international student population is relatively diverse in origin. More recently matriculated international students came from China, Egypt, India, Iran, Japan, Korea, Madagascar, Romania, Russia, Thailand, and Vietnam.
International Faculty and Visiting Scholars
Our tenured or tenure-tract faculty is internationally diverse. The Department of Pharmaceutical Sciences has international faculty from China, Greece, India, Indonesia, the Netherlands, United Kingdom, and Zimbabwe, which comprise 50% of the total faculty members in the department. The Department of Pharmacy Practice has one international faculty member.
The college also hosts international visiting professors and postdoctoral researchers. Last year, the college hosted one visiting professor from Chonnam University in Korea (Dr. Seung Hoon Cheon) and nine postdoctoral researchers from Cameroon, China, India, Japan, Korea, and Thailand.
In addition, the college of pharmacy hosts a study group of 15-20 Japanese pharmacists every year sponsored by the MSI group of Japan. In the last academic year, we hosted two study groups of Japanese pharmacists in October 2006 and May 2007).
Faculty International Activities
Our faculty has active international collaborations with scientists from China, Egypt, France, Germany, Indonesia, Japan, Korea, Panama, South Africa, Switzerland, and UK. One example is the collaboration of our faculty with Indonesian scientists in the investigation of natural products from Indonesian black water ecosystems. Black water ecosystems are poorly studied ecosystems spread across the Borneo and the Papua islands that are reported to have extreme physicochemical conditions but have enormous species richness. The collaborative project involves a group of Pharmaceutical Science faculty at OSU and scientists from the Indonesian Center for Biodiversity and Biotechnology (ICBB). Through this program, we were able to invite Dr. Dwi Andreas Santosa, the Director of ICBB, to come to OSU as a short term visiting scholar.
One of our faculty, Kerry McPhail, is also actively involved in the Panama International Cooperative Biodiversity Group. She frequently travels to Panama and actively collaborates with Panamanian scientists in the search for novel bioactive natural products from marine cyanobacteria.
Also, see appendix D that includes a list of faculty who have presented their research abroad.
b. Faculty recognition and awards
In collaboration with Mark Merickel in Extended Campus, the directors of pharmacy for several large employers (Bi-Mart, Fred Meyer, Safeway, and Samaritan Health Systems), and a business consultant from Linn Benton Community College, the college developed a 9 module, 18 hour web-based continuing education course for practicing pharmacists on human resource management. This course won an award from the University Continuing Education Association (UCEA) as the best course in the "distance learning course -- noncredit" category.
Angela Austin-Haney, Director of Student Services and Head Advisor
• Elected Secretary for the Northwest Association of Student Affairs Professionals (NWASAP)
• Completed her term as Chair-elect for the Academic Advising Council (AAC) this past year and will be Chair for the 07-08 year.
Gary DeLander
• President of the Rho Chi national pharmacy honorary society.
Theresa Filtz was promoted to associate professor
Ann Hamer, Dan Hartung, Dean Haxby, and Kathy Ketchum received the Journal of Managed Care Pharmacy (JMCP) Award for Excellence for their paper entitled “the use of prescription order change forms to achieve dose form optimization (consolidation and tablet splitting) of SSRI antidepressants in a state Medicaid program.”
Matt Ito
• Appointed as a board member of the Pacific Lipid Association which is the newest chapter of the National Lipid Association.
• Elected Treasurer of the Pacific Lipid Association for a term of 2 years.
• Appointed to the Credential Committee for the National Lipid Association.
Jane Ishmael was selected as Teacher of the Year by first professional year class
Wayne Kradjan elected President of the Oregon State Pharmacists Association
Taifo Mahmud
• Presented the Matt Suffness Award Lecture to the American Society of Pharmacognosy
• Featured in OSU This Week Volume 46 Number 4, Oct. 5, 2006.
• Honored with the 2007 Phi Kappa Phi Emerging Scholar Award.
• Selected to be a member of the Editorial Board of Perspectives in Medicinal Chemistry.
Deanna Moretz
• Elected Secretary for OSHP Board of Directors
• Co-chair for the OSHP Educational Affairs Committee
• Received Honorary Nursing Education Community Service Award from the Oregon Nurses Association on April 13, 2007.
Phil Proteau served as Chair of the Awards and Funds Committee at the American Society of Pharmacognosy
Dr. Rosita Proteau served as Chair of the Education Committee and Chair of the Minority Initiatives Subcommittee of the Society of Toxicology and President of the Regional Pacific Northwest Association of Toxicologists.
Stacy Ramirez
• appointed at the OSU Representative to the OSPA Board
• Elected Vice President of the Mid-Valley Housing Plus Board of Directors
• Featured in an article in Terra Magazine
Harleen Singh selected as Teacher of the Year by third professional year class.
Fred Stevens selected as Teacher of the Year by second professional year class.
Doug Stennett and Ann Zweber named co-recipients of the overall most influential Teacher of the Year by the graduating class of 2006-07.
Craig Williams. Accepted 2-year appointment as Associate Editor of Diabetes Forecast, a publication from the American Diabetes Association.
Ann Zweber was elected president of the Oregon Board of Pharmacy at the last meeting, June 6, 2007.
c. Student recognition and awards
Linda Wylie was the Oregon State University Representative to American Pharmacists Association-Academy of Students of Pharmacy (APhA-ASP) Patient Counseling Competition during their annual meeting in Atlanta, April 2007. Sara Hilbert served on the nominating committee and Mike Fahey served on the National Policy Committee. Mia Ha was APhA-ASP Region 7 Member at Large during the House of Delegates.
Sarah Hilbert served on the Leadership Development Subcommittee and the Affiliate Chapter Relations Committee of the American Society of Health Systems Pharmacists (ASHP). Roger Clark and Dan Rackham formed the team representing OSU at the ASHP Clinical Skills Competition during the ASHP Annual Meeting in Anaheim in December 2006.
Michelle Brown is the recipient of a Wal-Mart Graduate Student Travel Scholarship to attend the American Association Colleges of Pharmacy annual conference in Orlando.
Hugh Easley received the United States Public Health Service Excellence in Public Health Pharmacy Practice Award during the college’s graduation recognition ceremony in June.
Gaurav Bajaj, a senior graduate student in the laboratory of Dr. Jane Ishmael, was the recipient of the Neuron Award from the Oregon Chapter, Society for Neuroscience and presented MDR1 function is sensitive to the phosphorylation state of Myosin II Regulatory Light Chain at the annual chapter meeting in Portland on March 31.
The Sponenburgh Travel award was awarded to Gaurav Bajaj for his outstanding presentation at the April 2007 Annual Rising Lecture.
Undergraduate student Erik Coffman, a Biology major working in Chrissa Kioussi’s lab, was awarded HHMI Summer 2007 and URISC 2007 awards.
In December 2006, Acharawan Khamsiritrakul received a scholarship from the Delson Bridge to the Future Fund for graduating OSU Ph.D. students.
Uyen Minh Le was awarded an Oregon Sports Lottery Graduate Scholarship for 2007-08.
The Ayres Graduate Travel Award was given to Uyen Minh Le in recognition of her presentation at the April 2007 Annual Rising Lecture. Her presentation was entitled “Synergistic effect of synthetic dsRNA and a chemotherapy agent in inhibiting tumor growth.”
Yi-Chen Lee was awarded a supplemental Laurels Tuition scholarship from OSU for the 2007-08 academic year.
Brian Sloat, a graduate student in Zhengrong Cui’s laboratory received the P.F. and Nellie Buck Yerex Graduate Fellowship for 2007-08.
2. Strategic Plan Implementation: 2006-2007
a. For these three areas: enhancing student engagement and success, increasing research and outreach, and enhancing diversity and community, list the initiatives undertaken and the outcomes of each at the end of the year (include international dimensions within diversity)
▪ Provide a brief self-assessment of the unit efforts in the three areas: what worked; areas that need improvement; major barriers
Enhancing Student Engagement Success
Congruent with the university’s strategic plan, the college strives to pursue excellence in professional and graduate education by providing a faculty, curriculum, and learning environment that assures student access, retention, and success in the academic programs and throughout their professional careers. The college has an ongoing commitment to curricular review, systematic assessment, and enhancement. See the “initiatives in the support of teaching” section on pages two through seven in this report for an expanded description of this area.
Increasing Research and Outreach
See section on “Major research/scholarship initiatives” above (pages 7-10)
See section on “Major outreach/engagement initiatives” above (pages 10-11)
Enhancing Diversity and Community.
The College of Pharmacy Diversity Committee, chaired by Dr. Rosita Rodriguez Proteau, met frequently during the past year. The committee is charged to assist the college in meeting the university’s goals to: (1) attract diverse people including faculty, staff, and students; (2) ensure a welcoming and inclusive atmosphere; (3) assure that faculty, staff, and students demonstrate cultural sensitivity, including inclusion of these topics in curricular offerings; and (4) create an atmosphere where all can have a comfortable conversation about sensitive topics.
A comprehensive Diversity Action Plan was submitted to the University Director of Community and Diversity in October 2006. The plan includes a college-specific definition of diversity and corresponding diversity mission, vision, and value statements. The following five goals were established:
• Perform an assessment of retention of underrepresented and marginalized populations
• Increase diversity competency via a variety of faculty and staff training
• Promote and recognize the significant diversity that currently exists within the College of Pharmacy
• Identify barriers in the recruitment of student and faculty of color into pharmacy
• Establish faculty and student liaisons with the six cultural centers and disabilities services office at OSU as well as at the OHSU counterparts.
A copy of this document is attached as a separate attachment to this report. Progress was made on the first three goals with the last two goals to be addressed in the coming year. In particular, diversity training topics were included at all-college faculty and staff meetings twice during the past year and another training program is scheduled for the September 13 faculty meeting. As described earlier, the College Assessment Committee conducts annual “Learning Environment” surveys of the students and faculty to identify areas of needed emphasis (See appendix B). The results of this survey are used to inform the diversity committee of possible future actions.
The college advisors and the college’s director of alumni and student relations continue to attend many health career fairs, including those aimed at students in the Portland metropolitan area from high schools that have a high enrollment of underrepresented students. We also partner with OHSU as part of their Comprehensive Health Careers Opportunity Program (HCOP) grant which focuses on attracting disadvantaged students and minorities to careers in the health sciences. Because admission to the college requires a minimum of three years of prior college level coursework, recruitment aimed at high school students has a relatively low yield. For the last two years college advisors have visited the OSU cultural centers as an outreach to students already on campus.
b. Summarize major unit activities during 2006-2007 that helped promote one or more of the five thematic areas
Oregon State University’s Strategic Plan for the 21st Century indicates an aspiration to become a top 10 land grant institution. Among the five thematic focus areas of the university is to “realize fundamental contributions in the life sciences and optimizing the health and well being of the public.” As the strategic plan further states, “around these existing strengths, we will build an integrated and novel program focused on the prevention of disease, biomedical discovery and application, and the promotion of health.” An emerging area of specific strength poised for substantial growth within the health and life sciences theme relates to infectious disease research and drug discovery. The College of Pharmacy plays a leading role in advancing this theme as described in the section of this report entitled “major research and scholarship initiatives” (pages 7-10). The College of Pharmacy is committed to expanding its research programs in bioorganic chemistry and natural products (antibiotics) drug discovery as part of the statewide signature research initiative Oregon Translational Research and in Drug Discovery Initiative (OTRADI).
c. Summarize major accomplishments for 2006-2007 in support of the OSU Capital Campaign
The college of Pharmacy has three major initiatives for the capital campaign that parallel the university’s strategic plan and the mission of the college.
• Scholarships. Enhancing student engagement and success requires making the educational experience affordable and accessible. Endowed and current use scholarships, and other funds for student enrichment through the Dean’s Fund for Excellence contribute to goal to recruit Oregon’s best and brightest. Student support allows them to focus on their studies and maximize their educational pursuits. In addition to increasing annual fund contributions to scholarships, our goal is to obtain $1 million in new scholarship endowments over the course of the capital campaign. During the past year, two new $25,000 (John O’Connell and Krautscheid family) and one $100,000 (Philip Cash) endowed scholarships were established. In addition, the Zennie Stauffer Estate left $230,000 to the College to establish a scholarship. Part of the new Earl and Thelma Education Fund ($255,000) will be also used for scholarships. .
• Drug Discovery. The drug discovery and infectious diseases research initiatives of the college are described throughout this report. Current antibiotics are rapidly becoming ineffective in the face of new diseases and resistant microorganisms. At the same time, major drug companies are putting few resources toward developing new antibiotics. To fill the gap, pharmacy researchers are working to find compounds that hold promise as new antibiotics. An endowment of $1 million will help retain and attract faculty to accelerate this mission. Current-use funds will purchase equipment and other supplies. A pledge of $100,000 over five years in support of this initiative was received by the Steve and Jane Roath family. Steve is a college of pharmacy alumnus and member of the OSU Foundation Board.
• Progressive Pharmacy Practice and Entrepreneurship. Prescription drug therapies are a key ingredient to preventing emergence of life threatening diseases and improving the quality of life and productivity of patients with chronic illnesses. These life saving interventions are of little value if patients are not able to afford needed medications or if they do not take them correctly. Research has shown it is cost-effective and practical for a pharmacist to be the primary patient care specialist for certain disease states. The EMPOWER project in Lane County and the DURM Program described earlier in this report are the first steps of the college in developing innovative practice models and entrepreneurship. As part of the capital campaign agenda for the college, we propose to raise $1.5 million to establish an endowed program or professorship for innovative pharmacy practice that will serve the needs of the pharmacists of the state and improve the health of the citizens.
3. Other initiatives and their outcomes [e.g., Faculty/Staff Professional Development Activities]
Working closely with the Advancement Office, the College of Pharmacy Director of Alumni and Student relations redesigned all of the college marketing materials, application forms and the College Web Site. Two new table top displays (one for Corvallis and one for Portland), are now available to use for recruitment fairs and alumni events. All faculty, many alumni and students provided valuable input to assure that messages contained in these various media are accurate, up to date, and most importantly highlight the many great things happening in the college. There is a much greater use of color and pictures to tell our story, and all new materials conform to the latest branding messages of the university.
Primarily through the use of Foundation Funds, the college pays meeting registration and travel expenses for junior faculty to attend professional meetings, especially if they are presenting a paper or serving on a committee or task force. In particular, all faculty are encouraged to attend the annual meeting of the American Association of Colleges of Pharmacy. This organization offers programming aimed for new faculty orientation, improving teaching, and leadership training.
As part of their start up package, new faculty are encouraged and given funding to participate in the year long grant writing workshop coordinated by the College of Health and Human Sciences.
4. Scorecard
a. Performance on college-level metrics
The information in the tables on the next four pages was partially provided by the office of institutional research, with other sections generated by the college of pharmacy.
| |
|College of Pharmacy |
| |
| | | | | | | | |
| | | | | |
| | |2002-03 |2003-04 |2004-05 |2005-06 |2006-07 |2007-08 |
| | | | | | | | |
| | | | | | | | |
|1.2 |Invention Disclosures° |1 |4 |4 |3 |Jan-08 |- |
|1.4 |% of U.S. Minority Students of Total College Enrollment |37.0 |34.4 |32.3 |31.8 |34.0 |33.0 |
| | | | | | | | |
|2.2 |6-Year Graduation Rate (% Within College / % Within University) |N/A |N/A |N/A |N/A |N/A |N/A |
|2.3 |First Professional (PharmD) Degrees Awarded |55 |70 |64 |80 |Sep-07 |80 |
|2.4 |Graduate Degrees Awarded |10 |7 |7 |3 |Sep-07 |5 |
|2.5 |% of Seniors Participating in Student Engagement Activities / Number of |N/A |N/A |N/A |N/A |N/A |N/A |
| |Respondents | | | | | | |
|2.6 |Student Primary Major to Faculty FTE Ratio / Student Course to Faculty FTE|28.6 / 18.9 |30.3 / 19.1 |14.5 / 14.4 |13.0 / 13.3 |12.4 / 12.6 |- |
| |Ratio | | | | | | |
|2.x.1 |Pass Rate on NAPLEX Board Exam (%) |See separate |See separate |See separate |See separate |See separate |98 |
| | |table on next |table on next |table on next |table on next |table on next | |
| | |page |page |page |page |page | |
|3.2 |Private Giving Revenue |$315,670 |$215,145 |$302,565 |$631,497 |$659,356 |$500,000 |
|° Invention Disclosure data for FY 2005 and 2006 is reported based on fiscal year, while data for 2002-03 and 2003-04 are based on calendar years. This change was made for '05 and '06|
|so that the numbers correspond to the data period requested by the annual Association of University Technology Managers (AUTM) survey, completed by the OSU Office of Technology |
|Transfer. |
|* Estimated | | | | | | |
| | | | | | | | |
|Note: For FY 2003, 2004, and 2005, all awards affiliated with both a campus department and the OSU Extension Service were reported under the affiliated campus department. Beginning |
|FY 2006, these awards will be reported under the OSU Extension Service and not the campus department or college. |
| | | | | | | | |
Metric 2.x.1: Pass Rates on NAPLEX Licensing Board Examination
The National Association of Boards of Pharmacy (NABP) recently posted the five-year passing rates on licensing examinations for students from the US schools and colleges of pharmacy on their web site: ( ). The data indicate the passing percentages of first-time candidates for the North American Pharmacist Licensure Examination™ (NAPLEX®) and candidates for the Multistate Pharmacy Jurisprudence (law) Examination® (MPJE®) who graduated between 2002 and 2006 from United States schools and colleges of pharmacy accredited by the Accreditation Council for Pharmacy Education. Because the results are listed by calendar year, there is not always a direct correlation between number of candidates taking the exam and the number of graduates at the end of the academic year.
NAPLEX results
Out of 89 reporting Universities, five-year first time pass rates ranged from 75.53% to 99.78%, with a mean of 95.7%. Oregon State University ranked number12 among US schools with two or more years of reported results.
Year Candidates First Time Pass Rate
OSU graduates
2002 7 100%
2003 41 97.56%
2004 79 98.73%
2005 65 96.9%
2006 76 98.68%
Five year total 268 98.13%
(Note: All candidates passed the examination on subsequent attempts)
MPJE results
Because every state has a unique jurisprudence exam, students often take multiple exams to allow them to practice in more that one state. Also, candidates may take jurisprudence exams in a different year from the NAPLEX exam. Thus, the number of candidates for the jurisprudence exam in any given year is larger than the number of candidates for the NAPLEX exam and for graduates in that calendar year. The way the results are listed does not easily allow for calculation of US averages or rankings.
Year Exams taken First time Pass rate
OSU graduates
2002 68 87.8%
2003 78 94.87%
2004 124 95.97%
2005 127 91.34%
2006 147 91.16%
Five year total 544 92.28
(Note: all candidates passed the examination on subsequent attempts.)
Metric 2x.2. Pharm. D. Graduation rates
The College of Pharmacy Office of Student Affairs is able to track all students who enter the professional degree program to provide an accurate assessment of on-time and total graduation rates for each entering cohort of students. The table below provides the data for all students entering the college since the conversion to the entry level Pharm. D. degree program in 1999. Remarkably, four year graduation rates average greater than 85% and overall success exceeds 90%. Most students who delay graduation or leave the program do so for personal reasons, not academic difficulty, reflecting the older age of the student population (mean age 25 years on admission.)
|Entering Class year |Size of Class |Graduate in four years |Total Graduates |
|Fall 1999 |69 |June 2003: 56 (81%) |63 (91%) |
|Fall 2000 |78 |June 2004: 66 (85%) |76 (97%) |
|Fall 2001 |72 |June 2005: 57 (79%) |68 (94%) |
|Fall 2002 |78 |June 2006: 66 (85%) |69 (88%) |
|Fall 2003 |83 |June 2007: 76 (92%) |81 (98%) (estimated) |
|Fall 2004 |83 |June 2008: 71 (86%) (estimated) |79 (95%)(estimated) |
|Fall 2005 |85 |June 2009: 75 (88%) estimated) |84 (99%) (estimated) |
|Fall 2006 |88 |June 2010: 83 (94%) (estimated) |86 (98%) estimated |
|Fall 2007 |93 (estimated) |June 2011 | |
b. Leveraging resources
▪ Initiatives to leverage state resources
Pharm. D. tuition was raised by $2, 500 per year for incoming Pharm. D. students in 2006, and will increase an additional $1,000 per year for the next two academic years. Revenues from the differential tuition are returned directly to the college to hire new faculty, address faculty salary inequities, enhance the student learning experience, and pay for increased expenses associated with moving to the new building in Portland.
▪ Initiatives to improve administrative efficiencies
None to report
5. Assessment of your 2006-2007 Priorities
Provide a Brief assessment of your 2006-2007 priorities, including a self-assessment of what worked, what did not, and lessons learned.
Successes based on last year’s goals
• Improved budget allocation following approval of a significant increase in professional student tuition.
• Faculty salaries moved closer to those of peer institutions following a special 4% salary allocation in September 2006 to address compression and inequities and an additional 4% merit pool in January of 2007.
• The move to new offices, classrooms, and student space in the Center for Health and Healing building on the OHSU campus has improved student services and faculty morale.
• Hiring of several new faculty for both the Corvallis and Portland campuses that address teaching needs and will lead to greater research productivity over time.
• The Pharm. D. curriculum continues to be improved and refined as we review and implement recommendations from the assessment surveys that were part of the accreditation self-study.
• Completion of the self-study and site visit for the Graduate Program review. We anticipate continued approval of our modestly sized, but outstanding graduate program later this summer.
• Continuing support and growth of the research agenda around drug discovery, infectious diseases, developing and refining models of disease and drug action using models of genetically modified mice, cardiovascular diseases, and clinical pharmacokinetics. Recognition of OTRADI as one of the legislative funded signature research programs as part of the Oregon Innovation Council. Research funding increased to an estimated $2.6 million.
• Capital Campaign gifts and pledges of $659,000 including several new endowed scholarships and estate plans.
• Continuing to serve the Oregon Medical Assistance Program (OMAP) and Care Oregon through the college’s Drug Use Research and Management (DURM) program.
• Expansion of the EMPOWER Project.
• Actuating the college Diversity Plan Committee
New and Continuing Challenges
• The OUS does not have a clearly defined “cell value” for RAM funding of resident Pharm. D. students. Using a graduate level cell value is inappropriate and does not recognize the true cost of professional education. Approximately 90% of the College of Pharmacy E&G budget can be accounted for by student tuition.
• The recent resignation of the Director for Advanced Experiential Programs creates a significant gap in meeting student needs at a time when accreditation standards are placing increased emphasis on this component of professional education and a new college of pharmacy at Pacific University is adding increased competition for practice sites. Other faculty supporting this part of the curriculum are newly hired in the last year with a need for significant mentoring.
• There is a continuing need to better define our relationship with OHSU and long range planning for growth in the Portland area.
• To enhance efforts to support students and preceptors at distance sites for the experiential program, and to remain competitive with Pacific University, will likely require hiring of regional faculty coordinators (e.g., in Central and Southern Oregon). At the same time we need to explore collaborations with OSU Extension and the OSU Cascades Campus.
• While we have experienced considerable growth in faculty in Portland, there are several challenges to meeting the needs of students and research growth on the Corvallis campus. The most immediate concern is the impending full retirement of the faculty member in Corvallis who serves as co-coordinator of the second year pharmacy practice lab. (Also, see below regarding Student Health Service Pharmacy for an additional stress placed on delivery of this course for the coming year.) At the same time, we are reliant on part time and non-tenure track faculty to teach health care policy/public health, drug information/ informatics, law, and part of the pharmaceutics course series on the Corvallis campus. It is important that we stabilize at least some of these positions with research active tenure track faculty.
• Declining revenues and increased university overhead for the Student Health Service Pharmacy that require elimination of 1.0 FTE pharmacist and reduced access for the director to assist in the second year pharmacy practice laboratory.
• Coordination of the student experience, articulation of a seamless curriculum, and a desire to increase collaborative research across two campuses (Corvallis and Portland).
• We make extensive use of teleconferencing for faculty and student committee meetings, but current educational technology for distance learning is inadequate.
• Declining success rates by both senior and junior faculty for federal grant funding despite exceptionally high scores from study groups.
• A shortage of research space on both campuses.
• The college did not have a Development Director during the past year, making it difficult to make progress on capital campaign priorities. A new 0.5 FTE development director joined the college in May.
“Lessons learned” include the following:
• Substantial increases in professional student tuition are being used as a mechanism to achieve greater independence from state sources, but this is not a sustainable long term solution as competition increases from Pacific University and other regional programs that have greater overall support.
• Increasing competition from the new college of pharmacy at Pacific University is making it increasingly difficult to compete for practice sites. Possible solutions to consider (all with substantial associated costs) include increasing the number of practice based faculty, establishing regional coordinator positions, and/or providing financial incentives to external preceptors.
• The College of Pharmacy offers a joint professional degree with OHSU. With the recent change in Presidency at OHSU and their acquisition of new property on the waterfront, momentum is building to develop a new health sciences campus (Schnitzer Campus) that will emphasize interdisciplinary learning. It is envisioned that the College of Pharmacy will be part of that new campus. Analysis and planning must begin to determine the best future configuration of the College of Pharmacy (e.g., will the entire program move to Portland? Should we follow a model closer to that of OSU or OHSU?)
• Changes at the National Institutes of Health in funding priorities and decreases in overall real dollar funding levels required a re-examination of our R01 research programs and strategies for retaining funding. As a result, hiring in both departments has become more focused on building collaborative groups around common research themes (e.g. the anti-infectives medicinal chemistry initiative and the mutant mouse models of disease initiative in pharmacology). We will also see an increased reliance on alternative funding opportunities such as the signature research center proposal descried elsewhere in this report.
• We need to increase research collaborations with OHSU, especially the new Oregon Clinical and Translational Research Institute and the Oregon Evidence Based Practice Center.
• While we have made progress in improving the student experience in Portland, there are tensions between faculty in the department of pharmacy practice that require attention.
• Retention of Pharmacy Practice faculty with clinical skills will continue to be challenge as long as market forces continue to push pharmacists’ salaries that are significantly higher than current faculty salaries.
• Similarly, retention and promotion of PhD faculty will be a challenge without improved salary packages and without building a support network for collaborative research within disciplines. Recent hires have been targeted to build areas of common research strength.
• Our faculty strongly believe that the university and the research office must be proactive in seeking mechanisms for greater support of collaborative research programs and the infrastructure of core services such as mass spectrometry, NMR, and animal facilities.
• There is a need to grow our academic programs to address the continuing shortage of pharmacists while at the same time increasing efficiencies of instruction without adversely affecting our current high quality of instruction in academic, clinical, ethical and professional skills. Initial discussions to explore the possibilities of developing branch campuses around the state, and using video and distance learning technology to provide instruction with existing faculty, have begun. In addition to potentially increasing tuition revenue, such an initiative may also improve the ability of the college to recruit a more diverse student population and provide better pharmacy service to more remote regions of Oregon.
• Identification of barriers to recruitment of students, faculty and staff from underrepresented populations will require a focused effort on the part of the entire faculty with the coordination of the diversity committee and input from experts at the University level. The development of the colleges Diversity Action Plan is the first step in this process.
6. Proposed Priorities for 2007-2008
The following unique priority is listed first as an overarching issue for consideration. The remainder of the priorities follows the standard sections of Student Engagement and Success, Research and Scholarship, and Diversity.
• Engage a consultant to provide a roadmap for the future organization of the College of Pharmacy including OSU/OHSU reporting relationship; optimal funding model (e.g., RAM funding, distribution of tuition, semi-private); possible relocation to the Schnitzer Campus; and advisability of creating regional satellites in Central Oregon, Eugene, and Southern Oregon (for either experiential programs only or for the entire professional program.) Timing is critical relative to OHSU as they develop their strategic plan for 2020 that places a greater emphasis on interdisciplinary health sciences learning and research and the development of an entirely new academic campus. It is envisioned in that plan that the College of Pharmacy will have a central presence in the new academic campus. Similarly, Central Oregon and Cascades Campus represent a major collaborative opportunity for the College of Pharmacy to help build the identity of the Cascades campus, to take advantage of the clinical and research linkages with the St. Charles Medical Center, and to strengthen research partnerships with companies like Bend Research. While this will require new resources for faculty and office space, we are at risk of competition with other programs (e.g., Pacific University) if we do not act quickly.
▪ Student Engagement and Success
• Continued curricular review with an emphasis on integrating basic science courses and therapeutics in the second professional year and also coordinating the pharmacy administration/health outcomes course series.
• Review the Academic and Professional Standards documents to better articulate the admission, retention, and graduation requirements
• Relocate the Director of Alumni and Student Relations to Portland
• Continue to improve access to academic advising for students in Portland
• Complete the search for a new faculty member to co-coordinate the second year pharmacy practice course sequence.
• Explore the resources needed to develop a graduate pathway in pharmacy practice with an emphasis on pharmacoeconomics and pharmacoepidemiology.
• Begin a new community residency program in collaboration with Fred Meyer Pharmacies.
• Meet with advisors from the College of Science to identify efficiencies in advising of pre-pharmacy students at OSU.
▪ Increasing research/scholarship and outreach
• Rebuild a critical mass of faculty in the Pharmaceutics Research Area. A search committee has already been initiated for a new position in Pharmaceutics with an emphasis on novel mechanisms of drug delivery. This person will also be expected to contribute to the Pharmaceutics/Biopharmaceutics course sequence in the professional program.
• Build a stronger relationship with the OHSU Translational Research Center for faculty on both the Corvallis and Portland Campuses. This should be a high priority for the Assistant Dean for Scholarship and the Chair of Pharmacy Practice.
• Invest further in the Drug Discovery/ Infectious Disease Research initiative (new faculty hires and collaborations with the Colleges of Veterinary Medicine and Science and OHSU).
• Invest further in the genetically modified mouse model research (new faculty hires and collaborations with investigators on campus and around the world).
• Expand the research facilities on the Portland campus for the infectious disease, cardiovascular and clinical pharmacokinetic research groups.
• Increase enrollment in the Pharmacy Graduate Program to meet a goal of at least 2.5 Ph.D. students per research active faculty member in Pharmaceutical Sciences, or 39 students.
▪ Enhancing diversity and community
As indicated on page 15 and described in greater detail the College’s Diversity Action Plan, the College has identified five planning priorities addressing diversity and community. These activities will continue in the next biennium.
▪ Capital Campaign
Priorities for the capital campaign are unchanged from 2006-07. We look forward to working closely with our new college development director for a renewed emphasis on visitations with alumni and other friends of the college.
Appendix A
|GRADUATING PHARMACY STUDENT SURVEY |
|SUMMARY REPORT FOR OREGON STATE UNIVERSITY |
| |
|Total number of responses: 56 |
Demographic Information
|Gender |Response Percent |Response Total |
|Male |37.5% |21 |
|Female |62.5% |35 |
Section I: Professional Competencies/Outcomes
|Indicate the degree to which you agree or disagree with these statements. |
| |
|8. gather and use specific information (e.g., patient |50% (28) |45% (25) |5% (3) |0% (0) |0% (0) |
|histories, medical records) to identify patient | | | | | |
|medication-related problems. | | | | | |
|9. develop a patient care plan to manage each |41% (23) |59% (33) |0% (0) |0% (0) |0% (0) |
|medication-related problem. | | | | | |
|10. work with the health care team to implement the |32% (18) |55% (31) |9% (5) |2% (1) |2% (1) |
|patient care plan. | | | | | |
|11. document pharmaceutical care activities. |34% (19) |61% (34) |4% (2) |0% (0) |2% (1) |
|12. interpret epidemiologic data relevant to specific |21% (12) |70% (39) |5% (3) |0% (0) |4% (2) |
|diseases and their management. | | | | | |
|13. interpret pharmacoeconomic data relevant to |11% (6) |68% (38) |16% (9) |4% (2) |2% (1) |
|specific diseases and their management. | | | | | |
|14. develop medication use criteria. |32% (18) |61% (34) |7% (4) |0% (0) |0% (0) |
|15. conduct and analyze medication use reviews. |32% (18) |61% (34) |5% (3) |2% (1) |0% (0) |
|16. identify and use risk reduction strategies to |27% (15) |61% (34) |11% (6) |2% (1) |0% (0) |
|minimize medication errors. | | | | | |
|17. communicate with patients, patients' agents, and |50% (28) |45% (25) |5% (3) |0% (0) |0% (0) |
|health care providers. | | | | | |
|18. exhibit professional attitudes and behaviors. |55% (31) |43% (24) |2% (1) |0% (0) |0% (0) |
|19. provide patient care in accordance with legal, |45% (25) |50% (28) |5% (3) |0% (0) |0% (0) |
|ethical, social, economic, and professional guidelines.| | | | | |
|20. assess the cost-effectiveness of a clinical service|25% (14) |55% (31) |16% (9) |2% (1) |2% (1) |
|in a patient care setting. | | | | | |
|21. work with other stakeholders (e.g., patients and |30% (17) |55% (31) |9% (5) |0% (0) |5% (3) |
|other health professionals) to engender a team approach| | | | | |
|to assure appropriate use of health care resources in | | | | | |
|providing patient care. | | | | | |
|22. assure that medication use systems minimize |29% (16) |46% (26) |20% (11) |0% (0) |5% (3) |
|medication errors. | | | | | |
|23. assure that medication use systems optimize patient|27% (15) |46% (26) |20% (11) |0% (0) |7% (4) |
|outcomes. | | | | | |
|24. interpret and apply drug use policy and health |20% (11) |57% (32) |18% (10) |2% (1) |4% (2) |
|policy. | | | | | |
|25. work with other stakeholders (e.g., patients and |30% (17) |59% (33) |9% (5) |0% (0) |2% (1) |
|other health professionals) to identify and resolve | | | | | |
|problems related to medication use. | | | | | |
|26. promote wellness and disease prevention services. |48% (27) |43% (24) |9% (5) |0% (0) |0% (0) |
|27. practice pharmacy in interprofessional and |39% (22) |46% (26) |14% (8) |0% (0) |0% (0) |
|collaborative practice settings. | | | | | |
|28. retrieve, evaluate and manage professional |43% (24) |52% (29) |5% (3) |0% (0) |0% (0) |
|information and literature. | | | | | |
|29. reflect critically on personal skills and actions |46% (26) |46% (26) |4% (2) |2% (1) |2% (1) |
|and make plans to improve when necessary. | | | | | |
|30. accept and respond to constructive feedback. |46% (26) |46% (26) |4% (2) |2% (1) |2% (1) |
SECTION II: Doctor of Pharmacy Curriculum
|Indicate the degree to which you agree or disagree with these statements. |
| |Strongly Agree |Agree |Disagree |Strongly |Unable to |
| | | | |Disagree |Comment |
|32. I developed the skills needed to prepare me for |43% (24) |52% (29) |4% (2) |2% (1) |0% (0) |
|continued learning after graduation. | | | | | |
|33. I was provided opportunities to engage in active |38% (21) |50% (28) |11% (6) |2% (1) |0% (0) |
|learning (e.g., laboratories, recitations, student | | | | | |
|portfolios, problem-based learning, in-class | | | | | |
|activities). | | | | | |
|34. I was encouraged to ask questions in class. |27% (15) |54% (30) |16% (9) |0% (0) |4% (2) |
|35. I am satisfied with the overall availability of |11% (6) |30% (17) |38% (21) |16% (9) |5% (3) |
|pharmacy-related elective courses. | | | | | |
|36. Course loads were reasonable and balanced. |14% (8) |62% (35) |23% (13) |0% (0) |0% (0) |
|37. The program included opportunities to develop |30% (17) |61% (34) |9% (5) |0% (0) |0% (0) |
|professional attitudes, ethics and behaviors. | | | | | |
SECTION III: Pharmacy Practice Experiences
|Indicate the degree to which you agree or disagree with these statements. |
| |Strongly Agree |Agree |Disagree |Strongly |Unable to |
| | | | |Disagree |Comment |
|39. My introductory pharmacy practice experiences |27% (15) |54% (30) |14% (8) |4% (2) |2% (1) |
|permitted my involvement in direct patient care | | | | | |
|responsibilities in both community and institutional | | | | | |
|settings. | | | | | |
|40. The sites available for introductory pharmacy |23% (13) |52% (29) |12% (7) |5% (3) |7% (4) |
|practice experiences were of high quality. | | | | | |
|41. The process by which I was assigned sites for |23% (13) |59% (33) |14% (8) |4% (2) |0% (0) |
|introductory pharmacy practice experiences was | | | | | |
|satisfactory. | | | | | |
|42. Overall, my advanced practice experiences were of a|38% (21) |55% (31) |5% (3) |2% (1) |0% (0) |
|scope, intensity and duration necessary to support my | | | | | |
|achievement of professional competencies. | | | | | |
|43. During my advanced pharmacy practice experiences I |43% (24) |52% (29) |5% (3) |0% (0) |0% (0) |
|was able to develop my patient care skills in the | | | | | |
|community pharmacy setting. | | | | | |
|44. During my advanced pharmacy practice experiences I |52% (29) |41% (23) |5% (3) |2% (1) |0% (0) |
|was able to develop my patient care skills in a | | | | | |
|hospital or health-system pharmacy setting. | | | | | |
|45. During my advanced pharmacy practice experiences I |46% (26) |50% (28) |2% (1) |2% (1) |0% (0) |
|was able to develop my patient care skills in an | | | | | |
|ambulatory care clinic. | | | | | |
|46. During my advanced pharmacy practice experiences I |39% (22) |52% (29) |5% (3) |4% (2) |0% (0) |
|was able to develop my patient care skills in an | | | | | |
|inpatient/acute care hospital. | | | | | |
|47. The need for continuity of care throughout the |38% (21) |52% (29) |11% (6) |0% (0) |0% (0) |
|health care system was emphasized in the advanced | | | | | |
|pharmacy practice experiences. | | | | | |
|48. The variety of the available advanced pharmacy |41% (23) |52% (29) |4% (2) |4% (2) |0% (0) |
|practice experience electives met my needs as a | | | | | |
|student. | | | | | |
|49. I was academically prepared to enter my advanced |32% (18) |54% (30) |12% (7) |0% (0) |2% (1) |
|pharmacy practice experiences. | | | | | |
|50. The sites available for advanced pharmacy practice |38% (21) |55% (31) |5% (3) |2% (1) |0% (0) |
|experiences were of high quality. | | | | | |
|51. The process by which I was assigned sites for |39% (22) |50% (28) |7% (4) |4% (2) |0% (0) |
|advanced pharmacy practice experiences was | | | | | |
|satisfactory. | | | | | |
|52. My pharmacy practice experiences allowed me to have|48% (27) |48% (27) |4% (2) |0% (0) |0% (0) |
|direct interaction with diverse patient populations | | | | | |
|(e.g., age, gender, ethnic and/or cultural background, | | | | | |
|disease states, etc.). | | | | | |
|53. My pharmacy practice experiences allowed me to |48% (27) |41% (23) |11% (6) |0% (0) |0% (0) |
|collaborate with health care professionals other than | | | | | |
|pharmacists. | | | | | |
SECTION IV: Student Services
|Indicate the degree to which you agree or disagree with these statements. |
| |Strongly Agree |Agree |Disagree |Strongly |Did not Utilize |
| | | | |Disagree | |
|55. I am satisfied with the career planning and |9% (5) |43% (24) |32% (18) |4% (2) |12% (7) |
|guidance made available to me by the college/school. | | | | | |
|56. I am satisfied with the tutoring and academic |9% (5) |32% (18) |23% (13) |7% (4) |29% (16) |
|reinforcement services made available to me by the | | | | | |
|college/school. | | | | | |
|57. I am satisfied with the financial aid advisement |14% (8) |46% (26) |20% (11) |7% (4) |12% (7) |
|and guidance made available to me by the | | | | | |
|college/school. | | | | | |
|58. I am satisfied with the student health and wellness|12% (7) |54% (30) |7% (4) |9% (5) |18% (10) |
|services (e.g., counseling services, campus pharmacy, | | | | | |
|primary care clinics, etc.) made available to me by the| | | | | |
|college/school. | | | | | |
SECTION V: The Student Experience
|Indicate the degree to which you agree or disagree with these statements. |
| |Strongly Agree |Agree |Disagree |Strongly |Unable to |
| | | | |Disagree |Comment |
|60. Information was made available to me regarding |21% (12) |48% (27) |23% (13) |7% (4) |0% (0) |
|post-graduate education and training opportunities | | | | | |
|(e.g., residencies, fellowships, graduate school). | | | | | |
|61. The college/school's administration responded to |9% (5) |55% (31) |14% (8) |12% (7) |9% (5) |
|problems and issues of concern to the student body. | | | | | |
|62. A clear process existed for students to follow when|2% (1) |41% (23) |32% (18) |14% (8) |11% (6) |
|raising issues with the college/school administration. | | | | | |
|63. I was aware that student representatives served on |20% (11) |62% (35) |14% (8) |2% (1) |2% (1) |
|college/school committees with responsibility for | | | | | |
|curriculum and other matters. | | | | | |
|64. I experienced and/or witnessed incidents in which I|7% (4) |38% (21) |38% (21) |12% (7) |5% (3) |
|felt one of my classmates or I was discriminated | | | | | |
|against. | | | | | |
|65. The admissions process of the college/school of |29% (16) |62% (35) |2% (1) |2% (1) |5% (3) |
|pharmacy was satisfactory and well organized. | | | | | |
|66. The college/school of pharmacy had a student |16% (9) |48% (27) |18% (10) |5% (3) |12% (7) |
|government that effectively communicated student | | | | | |
|opinions and perspectives to the faculty or | | | | | |
|administration. | | | | | |
|67. The college/school of pharmacy made use of a |30% (17) |52% (29) |11% (6) |5% (3) |0% (0) |
|variety of means (e.g., course evaluations, student | | | | | |
|surveys, focus groups, meetings with administrative | | | | | |
|leaders) to obtain student perspectives on curriculum, | | | | | |
|student services, faculty/student relationships and | | | | | |
|other aspects of the program. | | | | | |
|68. The college/school of pharmacy provided an |18% (10) |52% (29) |27% (15) |4% (2) |0% (0) |
|environment and culture that promoted mutual respect | | | | | |
|among students and other members of the college/school | | | | | |
|community (e.g., faculty, administrators, staff). | | | | | |
|69. Faculty, administrators and staff were committed to|18% (10) |59% (33) |12% (7) |4% (2) |7% (4) |
|serving as positive role models for students. | | | | | |
|70. Overall, preceptors modeled professional attributes|38% (21) |54% (30) |7% (4) |0% (0) |2% (1) |
|and behaviors in the pharmacy practice experiences. | | | | | |
|71. Overall, preceptors provided me with individualized|32% (18) |59% (33) |7% (4) |2% (1) |0% (0) |
|instruction, guidance and evaluation that met my needs | | | | | |
|as a Doctor of Pharmacy student. | | | | | |
|72. I was aware of expected behaviors with respect to |55% (31) |43% (24) |2% (1) |0% (0) |0% (0) |
|professional and academic conduct. | | | | | |
|73. The college/school of pharmacy effectively managed |9% (5) |29% (16) |7% (4) |7% (4) |48% (27) |
|academic misconduct by students. | | | | | |
|74. The college/school of pharmacy effectively managed |7% (4) |25% (14) |7% (4) |9% (5) |52% (29) |
|professional misconduct by students. | | | | | |
|75. The college/school's administration and faculty |38% (21) |46% (26) |12% (7) |4% (2) |0% (0) |
|encouraged me to participate in regional, state or | | | | | |
|national pharmacy meetings | | | | | |
|76. The college/school of pharmacy was supportive of |39% (22) |46% (26) |9% (5) |0% (0) |5% (3) |
|student professional organizations. | | | | | |
|77. I was aware of opportunities to participate in |12% (7) |29% (16) |39% (22) |11% (6) |9% (5) |
|research activities with faculty. | | | | | |
SECTION VI: Facilities, Experiential Sites and Educational Resources
|Indicate the degree to which you agree or disagree with these statements. |
| |Strongly Agree |Agree |Disagree |Strongly |Unable to |
| | | | |Disagree |Comment |
|79. The computer and other information technology |20% (11) |52% (29) |21% (12) |7% (4) |0% (0) |
|resources provided by the college/school of pharmacy | | | | | |
|and/or elsewhere on campus met my needs. | | | | | |
|80. The laboratories and other simulated environments |12% (7) |64% (36) |18% (10) |5% (3) |0% (0) |
|(e.g., model pharmacy) of the college/school of | | | | | |
|pharmacy met my needs. | | | | | |
|81. The study areas available in the college/school of |20% (11) |55% (31) |20% (11) |5% (3) |0% (0) |
|pharmacy or elsewhere on campus met my needs. | | | | | |
|82. The common spaces such as lounges, lobbies or other|12% (7) |54% (30) |21% (12) |12% (7) |0% (0) |
|areas for relaxation and socialization available in the| | | | | |
|college/school of pharmacy or elsewhere on campus met | | | | | |
|my needs. | | | | | |
|83. On-campus access to educational resources (e.g., |38% (21) |46% (26) |11% (6) |5% (3) |0% (0) |
|library, electronic data bases, drug information | | | | | |
|center) met my needs. | | | | | |
|84. Off-campus (e.g., during experiential rotations) |46% (26) |39% (22) |7% (4) |5% (3) |2% (1) |
|access to educational resources (e.g., library, | | | | | |
|electronic data bases, drug information center) met my | | | | | |
|needs. | | | | | |
SECTION VII: Overall Impressions
|Indicate the degree to which you agree or disagree with these statements. |
| |Strongly Agree |Agree |Disagree |Strongly |Unable to |
| | | | |Disagree |Comment |
|86. The tuition and fees of the college/school of |12% (7) |38% (21) |41% (23) |7% (4) |2% (1) |
|pharmacy represented an acceptable value for the | | | | | |
|quality of education that I received. | | | | | |
|87. If I were starting my college career over again I |30% (17) |43% (24) |11% (6) |4% (2) |12% (7) |
|would choose to study pharmacy. | | | | | |
|88. If I were starting my pharmacy program over again I|23% (13) |32% (18) |25% (14) |7% (4) |12% (7) |
|would choose the same college/school of pharmacy. | | | | | |
|89. I would recommend a career in pharmacy to a friend |45% (25) |43% (24) |7% (4) |4% (2) |2% (1) |
|or relative. | | | | | |
Appendix B
Oregon State University
College of Pharmacy
LEARNING ENVIRONMENT SURVEY
2006
Report
Submitted by the
Assessment Committee
Ann Zweber, chair
Gary DeLander, ex-officio
Shametrice Davis
Theresa Filtz
Bryan Ing
Harleen Singh
Deanna Moretz
Tracy Shiozawa
Ted Williams
Introduction
The plan for assessment encompasses a range of areas within the College’s mission and goals. For 2005-2006, the Assessment committee focused its attention on the learning environment, the curriculum, and the graduate program. Within each area, the committee identified goals, and implemented assessment tools. A survey was constructed to assist with assessment of the learning environment. Information elicited from the survey will help guide committees and decision makers for the specific content areas. The committee will request reports from decision makers to identify changes that resulted from the assessments data. The Learning Environment Surveys will continue to be administered on an annual basis.
Student Learning Environment Surveys were conducted for each year of the program in the spring of 2005. Results of the surveys provided some insights into the College’s strengths and weaknesses in creating a quality learning experience for all students. The surveys were revised during the 2005-2006 academic year to reflect the programs current areas of attention for assessment. These include: curriculum, instructional technology and resources, college support and environment, professional development, overall experience, and demographic data.
Surveys were provided electronically using OSU’s BSG web-based survey tool. P1 students were asked to complete the survey in the Pharmacy Practice III lab during the last week of class in spring 2006. P2 students were invited to complete the survey after their final close-out exam for the Pharmacy Practice VI lab. P3 students were asked to complete the survey during their last week of Pharmacokinetics. Computers were available for all students at the time they were asked to complete the survey. In the P3 class, however, some computers may have been out of service, and some students completed the survey at a later time.
Level of agreement questions used the following scale:
1 = strongly agree
2 = agree
3 = neutral
4 = disagree
5 = strongly disagree
Means and standard deviations were calculated for each group of class responses. The number of students who completed the survey for each class was:
-------------------------------------------------------------------------------------------------------------------
Learning Environment Survey 2006
Instructional Technology and Resources Report
To: College Council, Library Resources Committee
INTRODUCTION
As part of the OSU College of Pharmacy Assessment Plan, the Assessment Committee developed and implemented a Learning Environment Survey for P1, P2, and P3 students in the spring 2006. A section of the survey asked students to provide information about Instructional Technology and Resources. Survey data can be found in Section II of the Learning Environment Survey Report. A summary is provided below.
SUMMARY
• First year (P1) and second year (P2) students at the Corvallis campus generally agreed that on-campus instructional, research, and study facilities were adequate for learning. Third year (P3) students at the Portland campus were notably less satisfied with how the facilities supported their learning.
• There was no consensus opinion for P1 and P2 students on the use of literature retrieval systems other than those provided by OSU. Data was not available for P3 students.
• P1 and P2 students were generally more satisfied with instructional techniques and technologies that P3 students.
• Both P1 and P2 were generally satisfied with all presented instructional techniques, with a preference for computer base and online instructional tools. P3s overall were less satisfied with instructional techniques and had a smaller bias for online instructional techniques than either P1 or P2 students.
• Most responding P1, P2 and P3 students characterized themselves as visual and interactive learners.
• Overall P1 and P2 students found electronic sources particularly effective. The P1 students mentioned Blackboard, PowerPoint, and the student website (P1wiki) regularly. The P2 students had a strong preference for PowerPoint presentations. P3 students most frequently listed videos and PowerPoint as being particularly effective.
• The most common complaints for students in all three years were the audio feedback and static in the microphones and overall classroom conditions in the primary instruction rooms. Other complaints generally focused on the presentation style, rather than the technology used. P3 students commonly listed poorly designed PowerPoint presentations.
• P3 students were the only group listing significant document retrieval issues. The primary complaint was a lack of an adequate interlibrary loan system at the Portland campus.
• It should be noted that in almost all areas of the survey (not just instructional resources) P3 responses reflected a higher level of dissatisfaction than P1 or P2 responses.
RECOMMENDATION
In light of the changing learning environment, the assessment committee recommends that the College administration consider the formation of an Instructional Support committee. It may be possible to reconfigure the Library Resources committee to evaluate and address issues related to resources for teaching and learning.
REQUEST FOR RESPONSE
The assessment committee is charged with prioritizing, implementing, and evaluating assessments for the College of Pharmacy and tracking changes resulting from assessments. To complete the cycle of assessment, it is essential for the committee to receive a response from decision making committees. The assessment committee requests a brief report from the executive committee describing changes that are being considered or implemented as influenced by the 2006 Learning Environment Survey. The report should be made no later than the end of the 2006-2007 academic year. Feedback and requests for additional assessments are welcome.
Submitted November 2006
Assessment Committee
Ann Zweber, Chair
Theresa Filtz
Deanna Moretz
Harleen Singh
Shametrice Davis, GTA
Tracy Shiozawa (P4)
Bryan Ing (P3)
Ted Williams (P2)
AACP COF/ COD Task Force on Faculty Workforce. June 2007
OSPA president
Learning Environment Survey Results for 2007 and 2006
Level of agreement questions used the following scale:
1 = strongly agree
2 = agree
3 = neutral
4 = disagree
5 = strongly disagree
Means and standard deviations were calculated for each group of class responses. The number of students who completed the survey for each class was:
2007 P1 = 80 2006 P1= 77
2007 P2=57 2006 P2= 74
2007 P3=47 2006 P3= 70
Section I: CURRICULUM
| |P1 |P2 |P3 |
| |Mean |Mean |Mean |
| |2007 |2006 |2007 |
|Rate your level of agreement with the following |Mean |Mean |Mean |
|statements. |2007 |2006 |2007 |
|For the following statements, indicate your level |Mean |Mean |Mean |
|of agreement. My experience at OSU College of |2007 |2006 |2007 |
|Pharmacy found that the College... | | | |
|For the following |Mean |Mean |Mean |Mean |
|statements indicate |2007 |2006 |2007 |2006 |
|your level of | | | | |
|agreement. | | | | |
|Amount of Effort |2007 |2006 |2007 |2006 |
| |2007 |2006 |2007 |2006 |
| |2007 |2006 |2007 |
|Indicate your level of agreement |Mean |Mean |Mean |Mean |
|in regards to your overall |2007 |2006 |2007 |2006 |
|experience at OSU College of | | | | |
|Pharmacy. | | | | |
| |2007 |
|East Indian |1 |
|European-American, |1 |
|German/Finnish-American | |
|Japanese |1 |
|Middle Eastern |1 |
|Vietnamese |1 |
|Western European descent |1 |
What other dimensions of diversity would you use to describe yourself? Check all that apply.
| |P1 |P2 |P3 |
|Dimension |2007 |2006 |2007 |
|OSU |53 |30 |17 |
|Portland State University |4 |5 |7 |
|University of Oregon |4 |6 |2 |
|Not OSU |2 |0 |0 |
|California |1 |0 |0 |
|Community College & OSU |1 |0 |1 |
|Many different schools |1 |2 |0 |
|Montana |1 |0 |0 |
|Out of state |1 |0 |3 |
|Pomona College |1 |0 |0 |
|Southern Oregon University |1 |1 |0 |
|University of California, Davis |1 |1 |0 |
|University of Nevada, Reno |1 |0 |0 |
|Willamette |1 |1 |1 |
|LBCC |0 |1 |2 |
|OIT |0 |1 |0 |
|University of Portland |0 |1 |3 |
|WSU |0 |1 |1 |
|College of the Siskiyous |0 |0 |1 |
|Eastern Oregon University |0 |0 |1 |
|Loyola University Chicago |0 |0 |1 |
|UK |0 |0 |1 |
|N/A |7 |0 |0 |
Did you have a Bachelor’s degree prior to starting the Pharm.D. program?
| |P1 |P2 |P3 |Total |
|Yes |47 |32 |27 |106 |
|No |31 |23 |18 |72 |
Appendix C
Grants and Contracts
(Listed alphabetically by PI; College of Pharmacy faculty noted in bold font)
Pharmaceutical Sciences
Zhengrong Cui
• ORCAL Chemicals Inc., Evaluation of the Anti-Tumor Activity of Metam Sodium-Potential Orphan Drug Class, $6,735
• ORCAL Chemicals, Inc., Evaluation of the Anti-Tumor Activity of Metam Sodium, Sulforaphane, and possible third plant phenol, $7,010.
• ORCAL Chemicals, Inc., Evaluation of the Anti-Tumor Activity of Metam Sodium, $17,750.
• American Association of Colleges of Pharmacy New Investigator Award, Development and validation of a Novel Dual-antigen Nasal Anthrax Vaccine, $10,244.
• Is participating ($50,000) in a University of Michigan, EBS Pilot Grant in Biodefense and Vaccinology entitled “Development and Evaluation of a Dual-antigen Brucella Vaccine”.
Theresa Filtz received the second installment of $66,000 of the three-year grant entitled “Determination of Active Principles of Crataegus Extract” from the American Heart Association.
Patricia Flatt was awarded $12,500 from the OSU Agricultural Research Foundation for her research proposal entitled “Genetic Engineering of Pseudomonas Fluorescens as Biocontrol Agents.”
Gitali Indra was granted $10,000 from the 2007 Oregon State University General Research funds.
Acharawan Khamsiritrakul A was selected for a Delson Bridge to the Future Fund award in the amount of $450 for Fall Term, 2006.
Chrissa Kioussi
• Research Equipment Reserve Fund - 2006-07 Solicitation for a "NanoDrop® ND-1000 UV-Vis Spectrophotometer".
• The March of Dimes, “Molecular Mechanisms of Cardiovascular Malformations”, $123,697.
• The American Heart Association, “AHA Control of Cardiovascular Development”, $116,675.
Kerry McPhail
• Two additional installments from the Smithsonian Institute for the study “Bioassay and Ecology Directed Drug Discovery in Panama”, totaling $145,496.
• $12,500 by the OSU Agricultural Research Foundation for her research proposal “A New Approach to the Chemical Investigation of Microbial Producers of Natural Herbicides’.
• Oregon Seed Council and Oregon Department of Agriculture for her project entitled “Alternatives to Field Burning, New Herbicidal Agents for the Control of Poa annua and Other Grassy Weeds,” $40,000
Taifo Mahmud
• Received the fourth installment of $225,414 of his four-year NIH RO1 grant entitled “Biosynthesis Approach to Novel Aminocyclitols”.
• Awarded $250,000 from the Herman-Frasch Foundation for his grant entitled Design of Novel Antifungal and Insecticidal Agents Using Validoxylamine A as a Scaffold.
Phil Proteau P
• Granted funding for his proposal entitled “Diterpene Antibiotic Biosynthetic Studies” submitted in response to the General Research Fund Fall 2006-7 Award Announcement.
• Received funding for a "Fourier Transform Infrared (FTIR) Spectrophotometer" from the Research Equipment Reserve Fund - 2006-07 Solicitation.
Fred Stevens received the second installment of $300,134 of his five-year NIH/NHLBI RO1grant
“Ascorbyllation of Oxidized Lipids and Atherosclerosis” from the National Institute Of health. Cristobal Miranda is the co-principal investigator on this grant.
Mark Zabriskie has received the fourth installment of $234,156 from the NIH for his grant entitled “Biosynthesis of Antitubercular Nonribosomal Peptides”.
Pharmacy Practice
David Bearden, George Allen, J. Mark Christensen were awarded $13,889 from Tec Laboratories, Inc for their project entitled “In Vitro Evaluation of a Novel Topical Antiseptic versus Other Topical Agents against Community-acquired Methicillin-resistant Staphylococcus Aureus”.
Theresa Bianco, received $10,403 as a subcontract with OH&SU for the project entitled “Review Effectiveness and Identity Key Messages in Consultation With Evidence review and Synthesis Contractors.
Dean Haxby
• $902,000 for Oregon Medical Assistance Program Contract
• $211,503 for Care Oregon Contract
Dean Haxby, Daniel Hartung, Luke Middleton, T. Edlund, K.Weaver received $106,943 from the Oregon Health Policy and Research for their project “Improving Professional Prescribing Practices Using an Evidence-based Curriculum”.
Kathy Ketchum, Dean Haxby, Luke Middleton State Accident Insurance Fund (not-for-profit, state-chartered workers’ compensation company) service contract to provide pharmacy benefit consultation services for SAIF insured - $41,500.
Weaver K, Haxby D, Hartung DG, Middleton L, Edlund T. Improving professional prescribing through an evidence-based curriculum. $400,000 grant from the Attorney General Grant Program ($85,602 to OSU)
Dale Kraemer, Teresa Bianco, Wayne Kradjan, Judi Low, Stacy Ramirez received several awards for their project “Community Pharmacists Empowering Patients with Diabetes through Self Care”:
• $17,839 from the Sanofi-Aventis
• $30,000 from the Community Pharmacy Foundation
• $7,350 from the Schering Plough
• $1,200 from the Sanofi Aventis
Dale Kraemer received two grants as subcontracts with OHSU:
• $19,813 for the project “Improve Brain Tumor Therapy
• $ 29,720 for the project “Barrier to Antitumor Agents”
Moretz D, Miller G, Snarski C, Zweber A. Implementation of Pharmacy Education Management Software (PEMS). TRF. $9,500
Craig Williams has received $3,025 from AstraZeneca in support of the inaugural meeting of the Oregon Lipid and Vascular Biology Working Group. The group provided an outreach opportunity for the OSU COP to bring together local and regional expertise to discuss recent clinical developments in vascular biology
| | |College of Pharmacy Grant Awards in FY 07 | | | | |
| | | | | | | | |
|Haxby, Dean G |CO Support Mgmt of Pharmacy Benefit |Private |J1061A |CareOregon |$211,503 |07/01/06 |06/30/07 |
Williams, Craig D |AZ Oregon Lipid Working Group Mtg |Private |V0172A |AstraZeneca, International |$1,773 |12/04/06 |02/20/07 | | | | | | |New Awards Total |$1,404,268 | | | | | | | | | | | | | | | | | | | | | | | | | |Awards Renewed in FY 07 | | | | | | | | | | | | | | | | | | |Primary PI |Grant Title |Fund Type |Fund |Agency Name |Award |Project Start |Project End | | | | | | | | | | | | |Bianco, Theresa |OH&SU Review Effectiveness Reviews |Federal Funds |U0433A |Oregon Health & Sciences University |$10,403 |09/26/05 |09/25/07 |Subaward | |Cui, Zhengrong |EUPH Cervical Cancer Immunotherapy |Foundation |F0465A |Elsa U Pardee Foundation |$1,7267 |04/01/06 |12/31/07 | | |Filtz, Theresa |AHA Actv Principls-Crataegus Extrct |Private |J1034A |American Heart Association |$66,000 |01/01/06 |12/31/07 | | |Flatt, Patricia M |MRF Molecular Evolutn for Drug Dsgn |Foundation |F0447A |Medical Research Foundation of Oregon |$471 |03/01/06 |02/28/07 | | |Kioussi, Chrissa |MoD Cardiovascular Malformations |Private |J0984B |March of Dimes |$123,698 |06/01/05 |05/31/08 | | |Kioussi, Chrissa |AHA Control of Cardiovascular Devlp |Private |J0956B |American Heart Association |$116,676 |01/01/05 |12/31/07 | | |Kraemer, Dale F |S-A Pharmacists Empowering Patients |Private |V0156A |Sanofi Aventis |$17,839 |09/30/05 |09/30/07 | | |Kraemer, Dale F |OH&SU Improve Brain Tumor Therapy |Federal Funds |U0383A |Oregon Health & Sciences University |$19,813 |09/20/04 |06/30/07 |Subaward | |Mahmud, Taifo |PHS Novel Bioactive Aminocyclitols |Federal Funds |P0197A |Public Health Service-Infectious Dis |$225,414 |06/01/04 |05/31/08 | | |McPhail, Kerry L |SI Drug Discovery in Panama |Federal Funds |J0904B |Smithsonian Institute |$43,473 |09/27/03 |04/30/07 | | |McPhail, Kerry L |SI Drug Discovery in Panama |Federal Funds |J0904A |Smithsonian Institute |$102,123 |09/27/03 |04/30/07 | | |Stevens, Jan F |MRF Oxidative Stress & Vitamin C Sup |Foundation |F0448A |Medical Research Foundation of Oregon |$868 |03/01/06 |02/29/08 | | |Stevens, Jan F |MRF Oxidative Stress & Vitamin C Sup |Federal Funds |P0237A |DHHS/Public Health Service |$300,134 |05/05/06 |04/30/08 | | |Yin, Xihou |MRF Biosynthetic Gene Cluster |Foundation |F0429A |Medical Research Foundation of Oregon |$44 |09/01/05 |08/31/06 | | |Zabriskie, Mark |PHS Biosynthesis Anti-TB Peptides |Federal Funds |P0185A |Public Health Service-Pharmacology |$234,156 |09/30/03 |08/31/07 | | | | | | |Awards Renewed Total |$1,262,838 | | | | | | | | | | | | | | | | | | |Total Awards in FY 07 |$2,667,105 | | | | | | | | | | | | | | | | | | | | | | | | |
Appendix D
Publications, Presentations, Professional and Public Service by Faculty
(Listed alphabetically by College of Pharmacy Faculty, noted in bold font)
July 2006 through June 2007
Publications:
Pharmaceutical Sciences
Ursula Bechert, J. Mark Christensen, “Pharmacokinetics of Orally Administered Ibuprofen in African and Asian Elephants (Loxodonta Africana and Elephas Maximum), Journal of Zoo and Wildlife Medicine, 38 (2): 258-268, 2007.
J. Mark Christensen, “MRSA Staph Infections: Coming to a Town Near You” Occupational Health and Safety. articles/47212/, April 2007
Prapoch Watanalumerd, J. Mark Christensen, and James W. Ayres, “Pharmacokinetic Modeling and Simulation of Gastrointestinal Transit Effects of Plasma Concentration of Drug from Mixed Immediate-Release and Enteric-Coated Pellets,” Pharmaceutical Development and Technology, 12(2): 193-202, 2007.
UM Le, ZR Cui, Biodistribution and tumor-accumulation of gadolinium (Gd) encapsulated in long-circulating liposomes in tumor-bearing mice for potential neutron capture therapy, Int J Pharm., 320(1-2): 96-103, 2006.
Sloat BR, Cui Z., Nasal immunization with a dual antigen anthrax vaccine induced strong mucosal and systemic immune responses against toxins and bacilli. Vaccine, 24(40-41): 6405-13, 2006 Sep 29.
BR Sloat, ZR Cui, Nasal immunization with anthrax protective antigen protein adjuvanted with polyriboinosinic-polyribocytidylic acid induced strong mucosal and systemic immunities, Pharm. Res., 23(6): 1217-26, 2006.
ZR Cui, BR Sloat, Topical immunization onto mouse skin using a microemulsion incorporated with an anthrax protective antigen protein-encoding plasmid, Int J Pharm., 317(2): 187-91, 2006.
Cui Z, Qiu F. Synthetic double-stranded RNA poly(I:C) as a potent peptide vaccine adjuvant: therapeutic activity against human cervical cancer in a rodent model, Cancer Immunol Immunother, 55(10): 1267-79, 2006 Oct.
ZR Cui, F Qiu, CD4+ T helper cell response is required for memory in CD8+ T lymphocytes induced by a poly(I:C)-adjuvanted MHC I-restricted epitope, J Immunother, 30(2): 180-189, 2007.
Zhang, Y., W.K. Vogel, J.S. McCullar, and T.M. Filtz., Phospholipase C-βετα3 and
-βετα1 form homodimers, but not heterodimers, through catalytic and carboxy terminal domains, Mol. Pharmacol., 70: 860-868, 2006.
Long, S.R.; Carey, R.A.; Crofoot, K.M.; Proteau, P.J.; Filtz, T.M., ³Effect of Hawthorn (Crataegus oxycantha) Crude Extract and Chromatographic Fractions on Multiple Activities in a Cultured Cardiomyocyte Assay,² Phytomedicine, 13: 643-650, 2006.
McCullar JS, Malencik DA, Vogel WK, Crofoot KM, Anderson SR, Filtz TM. Calmodulin potentiates G beta gamma activation of phospholipase C-beta3, Biochem Pharmacol., 73(2): 270-8, January 15, 2007.
Von Borstel-Smith, M., K.M. Crofoot, R. Rodriguez-Proteau, and T.M. Filtz., Effects of phenytoin and carbamazepine on calcium transport in Caco-2 cells, Toxicology In Vitro, 21: 855-862, 2007.
Flatt, P.M.; Mahmud, T., Biosynthesis of Aminocyclitol-Aminoglycoside Antibiotics and Related Compound, Nat. Prod. Rep., 24: 358-392, 2007.
Indra AK, Castaneda E, Antal MC, Jiang M, Messaddeq N, Meng X, Loehr CV, Gariglio P, Kato S, Wahli W, Desvergne B, Metzger D, Chambon P., Malignant Transformation of DMBA/TPA-Induced Papillomas and Nevi in the Skin of Mice Selectively Lacking Retinoid-X-Receptor alpha in Epidermal Keratinocytes. J Invest Dermatol (NPG), February 15, 2007.
Rodius, S., Indra (nee Ganguli), G., Thibault, C., Pfister, V., Georges-Labouesse, E., Loss of a6 integrins in keratinocytes leads to an increase in TGFb and AP-1 signaling and in expression of differentiation genes, Journal of Cell. Physiology, 212: 439-49, 2007.
Collins, A., M. Larson, J. Pfaff and J.E. Ishmael., “Survival of Swiss-Webster mouse cerebellar granule neurons is promoted by a combination of potassium channel blockers,” Toxicology Letters, 171: 60-68 (2007)
Ishmael, J.E., Safic, M., Amparan, D., Vogel, W.K., Pham, T., Marley, K., Filtz, T.M. and Maier, C., Nonmuscle myosins II-B and Va are components of detergent-resistant membrane skeletons derived from mouse forebrain, Brain Research, 1143: 46-59, 2007.
Kioussi, C, Shih HP, Loflin J, Gross MK, Prediction of active nodes in the transcriptional network of neural tube patterning, Proc Natl Acad Sci U S A., 103(49):18621-6, Dec 5, 2006.
John Loflin, Nathan Lopez, Phil D. Whanger and Chrissa Kioussi, Selenoprotein W during development and oxidative stress, Journal of Inorganic Biochemistry, 100: 1679-1684, 2006.
Shih HP, Gross MK, Kioussi C, Expression pattern of the homeodomain transcription factor Pitx2 during muscle development, Gene Expr Patterns, 7(4): 441-51, 2007 Feb.
Muller, I; Weinig, S; Steinmetz, H; Kunze, B; Veluthoor, S; Mahmud, T; Müller, R. A Unique Mechanism for Methyl Ester Formation via an Amide Intermediate Found in Myxobacteria, Chembiochem., 7: 1197-1205, 2006.
Shih H.P., Gross, M.K. and Kioussi, C., Cranial Muscle Defects of Pitx2 Mutants Result from Specification Defects in the First Branchial Arch, Proc Natl Acad Sci U S A, 104(14:) 5907-5912, 2007.
Minagawa, K.; Zhang, Y.; Ito, T.; Bai, L.; Deng, Z.; Mahmud, T. ValC, a New Type of C7-Cyclitol Kinase Involved in the Biosynthesis of the Antifungal Agent Validamycin A, ChemBioChem., 8: 632-641, 2007.
Wu, X.; Flatt, P.M.; Schlörke, O.; Zeeck, A.; Dairi, T.; Mahmud, T., A Comparative Analysis of the Sugar Phosphate Cyclase Superfamily Involved in Primary and Secondary Metabolism, ChemBioChem., 8: 239-248, 2007.
Andersson, Mats X.; Hamberg, Mats; Kourtchenko, Olga; Brunnstroem, Aasa; McPhail, Kerry L.; Gerwick, William H.; Goebel, Cornelia; Feussner, Ivo; Ellerstroem, Mats. Oxylipin Profiling of the Hypersensitive Response in Arabidopsis thaliana: Formation of a Novel oxo-phytodienoic acid-containing galactolipid, arabidopside E, Journal of Biological Chemistry, 281(42), 31528-31537, 2006.
Kursar, T.A.; Caballero-George, C.; Capson, T.L.; Cubilla-Rios, L.; Gerwick, W.H.; Gupta, M.P.; Ibanez, A.; Linington, R.G.; McPhail, K.L.; Ortega-Barria, E.; Romero, L.I.; Solis, P.N.; Coley, P.D. “Securing Economic Benefits and Promoting Conservation through Bioprospecting,” Bioscience, 56: 1005-1012, 2006.
McPhail, K.L.; Correa J.; Linington, R.G.; González, J.; Ortega-Barría, E.; Capson, T.L.; Gerwick. W.H., Antimalarial Linear Lipopeptides from a Panamanian Strain of the Marine Cyanobacterium Lyngbya majuscule,” J. Nat. Prod., 70, 984 – 988, 2007
Colgate, E.C., Miranda, C.L. Stevens, J.F., Bray, T.M. and Ho, E. Xanthohumol, a prenylflavonoid derived from hops induces apoptosis and inhibits NF-kappaB activation in prostate epithelial cells, Cancer Letters, 246: 201-209, 2007.
Han, B., Stevens, J.F., Maier, C.S. Design, synthesis, and application of a hydrazide-functionalized isotope-coded affinity tag for the quantification of oxylipid-protein conjugates, Anal Chem, 79(9): 3342-54, 2007.
Fei, X.; Yin, X.; Zhang, L. and Zabriskie, T.M., The Roles of VioG and VioQ in the Incorporation and Modification of the Capreomycidine Residue in the Peptide Antibiotic Viomycin, J. Nat. Prod., 70: 618-622, 2007.
Yin, X. and Zabriskie, T.M., The Enduracidin Biosynthetic Gene Cluster from Streptomyces fungicidicus, Microbiology, 152: 2969-2983, 2006,
Zhen, Y.; Slanar, O.; Krausz, K.W.; Chen, C.; Slavik, J.; McPhail, K.L.; Zabriskie, T.M.; Perlik, F.; Gonzalez, F.J.; and Idle, J.R., 3,4-Dehydrodebrisoquine, A Novel Debrisoquine Metabolite formed from 4-Hydroxydebrisoquine that Impacts the CYP2D6 Metabolic Ratio, Drug Metab. Disp, 34: 1563-1574, 2006.
Pharmacy Practice
Garey KW, Rege M, Pai MP, Mingo DE, Suda KJ, Turpin RS, Bearden, D.T. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: A multi-institutional study. Clin Infect Dis 2006;43:25-31.
Chen H, Suda KJ, Turpin RS, Pai MP, Bearden, D.T, Garey KW. High- versus low-dose fluconazole therapy for empiric treatment of suspected invasive candidiasis among high-risk patients in the intensive care unit: a cost-effectiveness analysis. Curr Med Res Opin. 2007 May;23(5):1057-65.
Garey KW, Turpin RS, Bearden, D.T, Pai MP, Suda KJ. Economic analysis of inadequate fluconazole therapy in non-neutropenic patients with candidaemia: a multi-institutional study. Int J Antimicrob Agents. 2007 May;29(5):557-62.
Pai MP, Bearden, D.T. Antimicrobial dosing considerations in obese adult patients. Society of Infectious Diseases Pharmacists Newsletter, Winter 2007.
Hamer, A.M, Hartung, D.M, Haxby, D.G, Ketchum, K.L, Pollack DA. Initial results of the use of prescription order change forms to achieve dose form optimization (consolidation and tablet splitting) of SSRI antidepressants in a state Medicaid program. J Manag Care Pharm. 2006 Jul-Aug;12(6):449-56.
Hartung, D.M, Ketchum, K.L, Haxby, D.G. An evaluation of Oregon's evidence-based Practitioner-Managed Prescription Drug Plan. Health Aff (Millwood). 2006 Sep-Oct;25(5):1423-32.
Hartung, D.M, Middleton, L, Haxby, D.G, Koder, M, Ketchum, K.L, Chou R. Rates of adverse events of long-acting opioids in a state Medicaid program. Ann Pharmacother 2007;41:921-8.
Ito, M.K, Cheung RJ, Gupta EK, Birtcher KK, Chong PH, Bianco, T.M, Bleske BE. Key articles, guidelines, and consensus papers relative to the treatment of dyslipidemias-2005. Parmacotherapy. 2006 Jul;26(7):939-1010.
Ito, M.K, Talbert RL, Tsimikas S. Panel discussion. Pharmacotherapy. 2006 Jul;26(7 Pt 2):98S-101S.
Ito, M.K, Talbert RL, Tsimikas S. Statin-associated pleiotropy: possible beneficial effects beyond cholesterol reduction. Pharmacotherapy. 2006 Jul;26(7 Pt 2):85S-97S.
Ito, M.K, Marrs, J, Williams, C. Omacor Effects on Serum Lipids and Clinical Outcome. Am J Cardiol. 2006 Jan 1;99(1):145.
Neuwelt EA, Gilmer-Knight K, Lacy C, Nicholson HS, Kraemer, D.F, Doolittle ND, Hornig GW, Muldoon LL. Toxicity profile of delayed high dose sodium thiosulfate in children treated with carboplatin in conjunction with blood-brain-barrier disruption. Pediatric Blood & Cancer. 2006; 47:174-82.
Dobscha SK, Corson K, Hickam DH, Perrin NA, Kraemer, D.F, Gerrity MS. Depression decision support in primary care: a cluster randomized trial. Ann Intern Med. 2006 Oct 3;145(7):477-87.
Gilmer Knight KR, Kraemer, D.F, Winter C, Neuwelt EA: Early changes in auditory function as a result of platinum chemotherapy: use of extended high frequency audiometry and evoked distortion product otoacoustic emissions in pediatric ototoxicity monitoring. J Clin Oncol 2007 April 1; 25(10): 1190-1195.
Marrs, J.C. Family medicine pharmacy residency programs. Am J Health Sys Pharm. 2006 Oct 1(63)19:1803-5.
Marrs, J.C, Saseen JJ. Chronic stable angina: angiotensin converting enzyme inhibitor therapy and/or calcium channel blocker therapy: when is it indicated? J Pharm Technol 2006;22:271-80.
Marrs, J.C, Saseen JJ. Dipeptidyl peptidase-IV inhbitors: which patients are ideal candidates? Am J Health Sys Pharm. 2007;64:1261.
McGregor, J.C, Perencevich EN, Furuno JP, Langenberg P, Flannery K, Zhu J, Fink JC, Bradham DD, Harris AD. Comorbidity risk-adjustment measures were developed and validated for studies of antibiotic-resistant infections. J Clin Epidemiol. December 2006; 59(12): 1266-1273.
Lodise TP, Miller CD, Graves J, Furuno JP, McGregor, J.C, Lomaestro B, Graffunder E, McNutt LA. Clinical Prediction Tool to Identify Patients with Pseudomonas aeruginosa Respiratory Tract Infections at Greatest Risk for Multi-Drug Resistance. Antimicrob Agents Chemother. February 2007; 51(2): 417-422.
Osih R, McGregor, J.C, Rich SE, Moore AC, Furuno JP, Perencevich EN, Harris AD. Impact of Empiric Antibiotic Therapy on Outcomes in Patients with Pseudomonas aeruginosa Bacteremia. Antimicrob Agents Chemother. March 2007; 51(3): 839-844.
Furuno JP, Harris AD, Wright MO, Hartley DM, McGregor, J.C, Gaff HD, Hebden JN, Standiford HC, Perencevich EN; Value of Performing Active Surveillance Cultures on Intensive Care Unit Discharge for Detection of Methicillin-Resistant Staphylococcus aureus. Infect Control Hosp Epidemiol June 2007; 28(6): 666-670.
Lycette JL., Dul, C, Munar, M, Belle, D, Chui SY, Koop DR, Nichols CR. "Effect of Pregnancy on the Pharmacokinetics of Paclitaxel: A Case Report." Clinical Breast Cancer. October 2006 (Vol. 7, No. 04)
Williams, C.D. Controversies in managing cardiovascular disease in patients with chronic kidney disease. Pharmacotherapy Self Assessment Program (PSAP). 2007; 6th Ed. Book 2. Published April, 2007
Zweber, A, Book Review: Pharmaceutical Calculations Workbook, American Journal of Pharmaceutical Education, 70(5): article 122, 2006
Research Posters and Oral Presentations:
Pharmaceutical Sciences
Dr. John Block and Dr. Doug Henry (BIOSAR Research) presented the paper “Evaluation of Descriptors to Classify CYP 450 Substrates” at the American Chemical Society National Meeting in San Francisco, CA, on September 12, 2006.
Dr. John Block delivered a continuing education talk “Recent Advances in the Treatment of Obesity and Weight Control: Diet, Pharmacotherapy, Surgery and Exercise” at the Oregon State Pharmacy Association Annual Meeting in Salem on September 16, 2006.
Dr. John Block presented a two hour course on “Facts and Fallacies of Vitamins: Let the buyer beware!” on January 9, 2007, for the Academy of Lifelong Learning.
J. H. Block, New Views of Diabetes Products Including New Drugs for Its Treatment (Oregon State Pharmacy Association Spring Seminar, Portland and Medford)
J. H. Block and D. Henry, Evaluation of Descriptors that Discriminate between CYP metabolized substrates, American Chemical Society 233rd National Meeting (Division of Computers in Chemistry), Paper #195, Chicago, IL, March 27, 2007.
ZR Cui presented, "New applications in using synthetic dsRNA for tumor therapy" at the OHSU Department of Radiation Medicine on February 12, 2007.
DeLander, G presented “Pharmacology of Analgesics: Just the Basics” at the Lane County Pharmacists Association Annual Seminar and at OSPA Spring CE Days in Portland and Medford.
DeLander G, Zweber A, and Kuntz T. presented a poster entitled “Pharmacy Program Student Outcomes Assessment: Utility for curricular assessment and student self-evaluation” at the NABP Annual Meeting in Portland, OR on May 20, 2007.
Theresa Filtz presented “New Drugs and New Mechanisms” on September 16, 2006, for the Oregon State Pharmacists Association in Salem, OR.
Satin Salehi, Theresa M. Filtz, Shannon R. Long, and Kristi M. Crofoot presented “Himbacine blocks the negative chronotropic effect of hawthorn (crataegus oxycantha) extracts” at the Oregon Academy of Sciences meeting, Western Oregon University, February 2007.
Theresa M. Filtz, Cecily Bishop, Yong Zhang, and Fred Stormshak presented a poster at the American Society for Pharmacology and Experimental Therapeutics meeting on May 2, 2007, entitled “Progesterone regulation of oxytocin receptor through non-genomic actions.”
Flatt, P.M.; Wu, X.; Loper, J.; Mahmud, T. presented “Identification and functional analysis of the pyralomicin biosynthetic gene cluster” at the Volcano Conference, February 23-25, 2007, Pack Forest, Washington. (Oral Presentation)
Arup Indra presented the seminar entitled “Nuclear receptor signaling in melanoma skin cancer” in the Department of Biotechnology, Guha Research Institute, Calcutta University, in January 2007.
Arup Indra gave a seminar entitled “Function of retinoid-X-receptor ( (RXR () in skin cancer” presented in Indian Institute of Chemical Biology, INDIA in January 2007.
Gitali Indra, Xiobo Liang, Olga Golonzhka, Mark leid, Bohda Wasylyk, Joseph Abecassis and Arup Indra: Transcription factor (COUP-TF)-interacting protein (CTIP2) expression in human Head and Neck Squamous cell carcinoma (HNSCC). 2007 OSU College of Pharmacy Annual Retreat at Salishan Lodge, Oregon Coast, April 20-21, 2007.
Jane Ishmael, masa Safic,, david Amparan, Walter Vogel, Tuyen Pham, Kevin Marley, Theresa Filtz, and Claudia Maier. Presented a poster entitled Nonmuscle myosins II-B and Va are components of detergent-resistant membrane skeletons derived from mouse forebrain at the British Neuroscience Association 19th National Meeting, Harrogate, U.K. 3 April, 2007.
Jane Ishmael presented “Regulation of NMDA receptor function by a myosin light chain” at the School of Pharmacy, University of Bradford, Yorkshire, England. U.K. 4 April, 2007.
Appu M, Shih H.P., Porter G. Jr., Gross M.K., and Kioussi C., Homeobox Pitx2 Regulates Cardiac Outflow Tract Development by Controlling the Anterior/Secondary Heat Field Lineage, at the Ninth Annual Heart Research Center Scientist Retreat at OHSU on November 6, 2006. (won the Trainee Award for the poster presentation)
Chrissa Kioussi presented the following seminar on December 14, 2006; “The Genesis of a Healthy Muscle from Transcriptional Regulation to Diet” at the Linus Pauling Institute Seminar Series, Oregon State University.
Appu M, Shih H.P., Porter G. Jr., Gross M.K., Kioussi C. “The Homeobox Pitx2 Regulates Cardiac Outflow Tract Development by Controlling the Anterior/Secondary Heat Field Lineage”, a poster under the 'Students Poster Competition' Annual Meeting, American Association for the Advancement of Science(AAAS), February 15-19, 2007 at the Hilton in San Francisco. (received a registration award)
Shih H.P., Gross M.K., Kioussi C. Cranial Muscle Defects of Pitx2 Mutants Result from Specification Defects in the First Branchial Arch., Northwest Regional Developmental Biology Conference, Cold spring Harbor, WA, March 14-17, 2007. 1st prize Graduate Student Award
Mahmud, T. presented Biosynthesis of Aminocyclitol-containing Natural Products at Shanghai Jiaotong University on July 18, 2006, Shanghai, China, and at Xiamen University on July 20, 2006, Xiamen, China.
Flatt, P. M.; Wu, X.; Mahmud, T. Identification and Functional Analysis of the Pyralomicin Biosynthetic Gene Cluster. IUPAC International Conference on Biodiversity and Natural Products, July 23-25, 2006. Kyoto, Japan. (Oral and Poster Presentation)
Minagawa, K.; Zhang, Y.; Ito, T.; Bai, L.; Deng, Z.; Mahmud, T. Functional Analysis of the Cyclitol Kinase ValC Involved in Validamycin A Biosynthesis. American Society of Pharmacognosy 47th Annual Meeting, August 5-9, 2006, Arlington, Virginia. (Poster Presentation)
Mahmud, T. Biosynthetic Approaches to Novel Aminocyclitol-Containing Natural Products, American Society of Pharmacognosy 47th Annual Meeting, August 5-9, 2006, Arlington, Virginia. (Matt Suffness Award Lecture)
Mahmud, T. Biosynthetic Approaches to Novel Natural Products. Research Center for Marine and Fisheries Product Processing and Biotechnology Ministry of Marine Affairs and Fisheries Republic of Indonesia, August 31, 2006 Jakarta, Indonesia.
Mahmud, T. Harnessing the Biosynthetic Machineries of Microorganisms in Drug Discovery Efforts, Washington State University, October 9, 2006.
Mahmud, T. Antibiotics Drug Discovery. Presented to a group of Japanese Pharmacists at Oregon State University College of Pharmacy, October 17, 2006.
Mahmud, T. presented “Drug Discovery Research: Using Biosynthetic Machineries to Make New Chemical Entities” at the University of Louisville Department of Chemistry, January 10, 2007.
Fotso, S., Mahmud, T., Zabriskie, T.M. Proteau, P.J. and Santosa, D.A. presented the poster “Talomycins A~E, New Angucyclinones from an Indonesian Streptomyces sp” at the Volcano Conference on Chemical Biology, Pack Forest, Washington, in February 2007.
Minagawa, K.; Zhang, Y.; Ito, T., Bai, L.; Deng, Z.; Mahmud, T. presented the poster, “ValC, a new C7-cyclitol kinase involved in the biosynthesis of the antifungal agent validamycin A” at the Volcano Conference, February 23-25, 2007, Pack Forest, Washington.
Wu, X.; Flatt, P.M.; Mahmud, T. presented the poster, “Biosynthetic Study of Cetoniacytone A and a Comparative Analysis of the Sugar Phosphate Cyclase Superfamily Involved in Primary and Secondary Metabolism” at the Volcano Conference, February 23-25, 2007, Pack Forest, Washington.
Xu, H.; Bai, L.; Li, L.; Minagawa, K.; Yu, Y.; Zhang, Y.; Zhou, X.; Floss, H.G.; Deng, Z.; Mahmud, T. presented the poster, “Functional Analysis of the Validamycin Biosynthetic Gene Cluster and Engineered Production of Validoxylamine A” at the Volcano Conference, February 23-25, 2007, Pack Forest, Washington.
Kerry McPhail traveled to Egypt May 23-June 5, and gave an invited talk on June 4 in the Faculty of Pharmacy, Suez Canal University in Ismailia, entitled “Anticancer and Antimalarial Lead Compounds from Panamanian Cyanobacteria.”
Yao, Q. and Proteau, P.J., “Cloning the Diterpene Gene Cluster for the Fungal Antibiotic Pleuromutilin”; Poster presentation at the American Society of Pharmacognosy Meeting in Arlington, VA, August 5-9, 2006.
Ying Fan and Rosita Rodriguez-Proteau, Berberine and Berbamine Modulate P-glycoprotein. Society of Toxicology Annual Meeting, Charlotte, NC, March 2007.
Fred Stevens presented a seminar ‘Bioconjugation of lipid peroxidation products: A new role for vitamin C?’ at a Colloquium celebrating the 10th Anniversary of the Linus Pauling Institute at OSU, November 2, 2006, Corvallis, Oregon.
Fred Stevens presented “Ascorbylation Reactions” at the 4th International Conference on Diet and Optimum Health on May 16-19, 2007, in Portland, Oregon. This was an invited lecture. This conference was attended by 195 participants from 13 countries (USA, UK, Canada, Switzerland, Italy, France, the Netherlands, Austria, Georgia, Japan, Malaysia, South Korea and Australia) and it was jointly sponsored by the Linus Pauling Institute, Oregon Health & Science University and the Oxygen Club of California.
Kuiper, H.C. and Stevens, J.F. presented a lecture entitled “Glutathionylation of the Lipid Peroxidation Product, 4-Hydroxy-2-nonenal, in Humans” at the 4th International Conference on Diet and Optimum Health, May 16-19, 2007, in Portland, Oregon.
Kesinger, N.G., Gordillo, R., and Stevens, J.F. presented a poster entitled “Ascorbylation of Acrolein in Vivo. 4th International Conference on Diet and Optimum Health” on May 16-19, 2007, in Portland.
Miranda, C.L., Reed, R., Taylor, A., and Stevens, J.F. presented a poster entitled “Ascorbic Acid Protects Against 4-Hydroxynonenal (HNE) Toxicity in Endothelial Cells” at the 4th International Conference on Diet and Optimum Health, May 16-19, 2007, in Portland, Oregon.
Fred Stevens was invited to present the lecture “Xanthohumol and other beer flavonoids: To your good health?!” at the Bionovix Symposium on Xanthohumol in San Antonio, Texas, on 29 June 2007
Stevens, J.F., Reed, R., Taylor, A.W., Gordillo, R., and Miranda, C.L. presented a poster entitled “Bioconjugation of lipid peroxidation products: A new role for vitamin C?” at the 55th ASMS Conference on Mass Spectrometry and Allied Topics on June 3-7, 2007, in Indianapolis, Indiana.
Chavez, J., Han, B., Stevens, J.F. and Maier, C.S. gave an oral presentation at the 55th ASMS Conference on Mass Spectrometry and Allied Topics on June 3-7, 2007, in Indianapolis, Indiana, entitled “In vivo protein targets of reactive lipid peroxidation products”.
Xihou Yin, invited lecturer, “Genetic and Biochemical Approaches to Natural Products Peptide Antibiotics” at the International Chinese Bioscientist Symposium on Medical and Pharmaceutical Biotechnology, July 9-12, 2006. Nanjing, China.
Xihou Yin, invited lecturer, “Genetic and Biochemical Approaches to Natural Products Peptide Antibiotics” at the Jiangsu University, July 11, 2006. Zhenjiang, China.
Xihou Yin, seminar presenter for Professor Wang’s group at the Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences, July 14, 2006. Beijing, China.
Xihou Yin, Ying Tan, Ling Zhang and T. Mark Zabriskie. Abstract: “The Cloning, Sequence and Initial Characterization of the Enduracidin Biosynthetic Gene Cluster”, contributed to the International Chinese Bioscientist Symposium on Medical and Pharmaceutical Biotechnology, July 9-12, 2006. Nanjing, China.
Blanchard, D.L., Fei, X., Zhang, L., Yin, X. and Zabriskie, T.M., Enzymes Catalyzing Enduracididine Biosynthesis from the Enduracidin Gene Cluster, Volcano Conference on Chemical Biology, Pack Forest, Washington, February, 2007.
Fei, X., Yin, X. and Zabriskie, T.M. Incorporation and Modification of the Capreomycidine Residue in the Peptide Antibiotic Viomycin, Volcano Conference on Chemical Biology, Pack Forest, Washington, February, 2007
Zhang, L., Yin, X. and Zabriskie, T.M., Production of a New Enduracidin Analog by Gene Disruption, Volcano Conference on Chemical Biology, Pack Forest, Washington, February, 2007.
Pharmacy Practice
Allen GP, Xu Y. Analysis of the mutant prevention concentration and mutant selection window for fluoroquinolones against Haemophilus influenzae: evaluation of resistance selection in an in vitro pharmacodynamic model.. 46th Conference on Antimicrobial Agents and Chemotherapy (ICAAC). San Francisco, CA, September 2006
Allen GP, Hansen RE. Evaluation of the mutant prevention concentration for fluoroquinolones against Klebsiella pneumoniae and analysis of comparative fluoroquinolone resistance development in an in vitro pharmacodynamic model. 46th Conference on Antimicrobial Agents and Chemotherapy (ICAAC). San Francisco, CA, September 2006
Bearden DT. “It Really Is ALL Infectious Diseases: Human Papillomavirus, Another Vaccine-Preventable” Disease 2006 American Society of Health-System Pharmacist Midyear Meeting, Anaheim, California – December 7, 2006.
Bearden DT. “An update on infectious diseases.” Presented at the Naturopathic Medical Education Institute, Portland, Oregon, May 2007.
Belle D. “Pharmacogenomics” Oregon Society of Health-System Pharmacists Fall Seminar, Portland, OR – October 21, 2006.
Bianco TM. “The Role of Lipid Management in Cardiovascular Health” OSPA Annual Meeting at the Salem Convention Center, September 16, 2006.
Hamer A. "Achieving Dose Optimization of Mental Health Medications through Prescription Change Forms: Initial Results from a State Medicaid Program". Oregon Health Research & Evaluation Collaborative Meeting - December 12th, 2006
Hartung D. "Oregon's Experience with Implementing an Evidence-Based Practitioner Managed Prescription Drug Plan". Oregon Health Research & Evaluation Collaborative Meeting - December 12th, 2006
Ito MK. “New Data Sets for Statins, Nonstatins, and Diabetes for LDL-C Lowering.” Southwest Washington Pharmacist Association, Portland, OR - August 23, 2006
Ito MK. “New and Emerging Concepts in Cholesterol Management” Oregon Society of Health-System Pharmacists Fall Seminar, Portland, OR – October 21, 2006.
Ito MK. “Monotherapy and Combination Statin Therapy: Safety in Perspective” Updates in Pharmacy, Pri-Med Institutes, Boston, MA – October 26, 2006.
Ito MK. “Treatment of Metabolic Syndrome: What’s in the Guidelines?” 2006 Annual Meeting of the American College of Clinical Pharmacy, St. Louis, Missouri -October 28, 2006.
Ito MK. “Need to lower aggressively LDL in high-risk patients and how to achieve this” 2006 American Society of Health-System Pharmacist Midyear Meeting, Anaheim, California – December 4, 2006.
Ito MK. “Pharmacologic Approaches to the Management of Lipid Disorders: CHD Case Studies” The Lipid Management Certification Program at UCSF School of Pharmacy – January 10, 2007.
Ito MK. ”Non-Lipid Lowering Impact of Therapy Pleiotropic Effects of Statins “The Lipid Management Certification Program at UCSF School of Pharmacy – January 10, 2007.
Ito MK. “Lipoprotein Particle Size and Practical Issues in Lipid Clinic Management” Inaugural Scientific Forum of the Pacific Lipid Association, San Diego, California – January 21, 2007.
Ito MK. ” A Practical Approach to Today’s Treatments for Dyslipidemia” 2007 Fred Meyer Manager's Meeting - Where your health is our priority, Portland, Oregon – April 26, 2007.
Ito MK. “Strategies for Optimizing Adherence in High-Risk Patients” Pri-Med Institute, Updates in Pharmacy meeting. John B. Hynes Veterans Memorial Convention Center, Boston, MA - June 7, 2007.
Kradjan, W. “Clinical use of Adrenal Corticosteroids.” Presented at the Naturopathic Medical Education Institute, Portland, Oregon, May 2007.
Linares, R. and Zweber A. Value of offering a voluntary, noncredit course to teach pharmacy-based Spanish language skills. AACP Annual Meeting, San Diego, CA, July 10, 2006
Marrs JC. “New Agents for the Treatment of Insomnia in the Elderly” Professional Society of Pharmacists; Portland, OR: September 2006
Marrs JC. “New Agents for the Treatment of Insomnia” American College of Clinical Pharmacy Annual Meeting, St. Louis, MO: October 26-29, 2006
Marrs JC, Saseen JJ, Hansen LB, Nair KV. Lack of correlation between A1C and glycemic burden using a glycemic medication potency value. Abst#366 American College of Clinical Pharmacy Annual Meeting. October, 2006; St. Louis, MO
Marrs JC, Saseen JJ. “Dyslipidemia control in an indigent population with medication assistance compared to an insured population” American College of Clinical Pharmacy Spring Practice and Research Forum. April, 2007; Memphis, TN.
Marrs JC. “Chronic Stable Angina: Current Standards of Practice and New Pharmacotherapeutic Approaches” Marrs JC; OSHP Annual Seminar; Bend, OR: April 2007
McGregor JC, Rich SE, Harris AD, Perencevich EN, Furuno JP. A Systematic Review of the Methodologies Used to Assess the Association Between Appropriate Antibiotic Therapy and Outcomes in Bacteremic Patients. Poster presentation. 46th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA. Sept 27, 2006.
Osih R, McGregor JC, SE Rich, Furuno JP, Perencevich EN, Harris AD. Impact of initial empiric therapy on outcomes in Pseudomonas bacteremia. 46th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA. Sept. 2006.
Perencevich EN, McGregor JC, Furuno JP, Harris AD, Johnson JA. Seasonal variation in three nosocomial pathogens: Pseudomonas aeruginosa, Acinetobacter baumannii, and Staphylococcus aureus. 46th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA. Sept. 2006.
Furuno JP, Miller RR, Harris AD, McGregor JC, Perencevich EN. Evidence for age group-specific antibiograms to guide empiric therapy. 46rd Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA. Sept. 2006.
McGregor JC, Dumyati G, Casiano-Colon AE, Chang PJ, Klevens RM. Will Antibiograms Affect the Choice of Therapy in Pediatric Oupatients? Poster presentation. 44th Annual Meeting of the Infectious Diseases Society of America. Toronto, ON, Canada. Oct. 13, 2006.
Miller RR, Perencevich EN, Harris AD, McGregor JC, Lautenbach E, Furuno JP. Increase in Fluoroquinolone-Resistant Gram-Negative Clinical Cultures among Hospitalized Older Adults Over an Eight-year Period. 17th Annual Scientific Meeting of the Society for Healthcare Epidemiology of America. April 2007. Baltimore, MD.
Schweizer ML, Furuno JP, Harris AD, McGregor JC, Thom KA, Standiford HC, Hebden JN, Perencevich EN. Electronic Medical Record Indicators of Previous Colonization or Infection with Methicillin- resistant Staphylococcus aureus (MRSA) and Empiric Therapy for Suspected Bacteremia. 17th Annual Scientific Meeting of the Society for Healthcare Epidemiology of America. April 2007. Baltimore, MD.
Schweizer ML, Furuno JP, Harris AD, McGregor JC, Thom KA, Perencevich EN. Predictors of Methicillin-resistant Staphylococcus aureus (MRSA)-directed Empiric Therapy for Suspected Bacteremia. 40th Annual Scientific Meeting of the Society for Epidemiologic Research Meeting. June 21, 2007. Boston, MA.
Moretz D. Oregon State Pharmaceutical Association - Annual Meeting, Student Track- September 16, 2006 "Residencies, Fellowships, or Practice - What Should I Do After Graduation?"
Moretz D. Oregon Nurses Association - October 26, 2006 "Pharmacy Perspectives on Pain Management"
Moretz D. Professional Society of Pharmacists - November 5, 2006 "Pain Management Overview"
Moretz D. February 15, 2007 - Nursing Pain Management Seminar, Wellspring through Silverton Hospital.
Moretz D. Friday, February 23, 2007 - OHSU Multicultural Health, Science and Engineering Career Conference
Bubalo J, Tse S, Munar MY. A Pilot Study of Aprepitant vs Placebo Combined with Standard Antiemetics for the Control of Nausea and Vomiting During Hematopoietic Cell Transplantation. Poster presentation at the American Society of Clinical Oncology meeting, June 1-5, 2007, Chicago, IL.
Ramirez S. “Medication Errors” OSPA Annual Meeting at the Salem Convention Center, September 16, 2006.
Williams C. Presented the ASPEN study to the Lipid Journal Club at OHSU. October 24, 2006. Lipid club is a multidisciplinary meeting attended by approximately 20 researchers and clinicians on the OHSU campus.
Williams CD. "Statins, stroke and the SPARCL trial" presented at weekly OHSU lipid journal club, December 5, 2006.
Williams CD. “Dual anti-platelet therapy” Presented at Oregon Society of Health-System Pharmacists meeting. Sun River, OR April, 2007
Williams CD. Changes in ambulatory-measured blood pressure with LDL apheresis. Presented as poster at National Lipid Association Meeting, Phoenix AZ. May 2007
Williams CD. Omega-3 fatty acids and CVD: The JELIS trial. Presented to Endocrinology Divisions’ Lipid Club, OHSU Hospital. May, 2007
Zweber, A, Assessing Communication Skills, Including English Language Proficiency, in the Interview Process, AACP Annual Meeting, San Diego, CA, July 8, 2006
Zweber A. Providing Culturally Competent Care: Reflecting and Connecting, St. John’s University Pharmacy Congress, Queens, NY, November 1, 2006
Conry J, Roche V, Zweber A, Underserved Curriculum Task Force Open Forum, American Association of Colleges of Pharmacy Interim Meeting, Arlington, VA February 6, 2007
Clark P and Zweber A, Pharmacy Law: Pain CE and PDMPs, General Rules
Update, Oregon State Pharmacists Association Spring CE Meeting, Portland, OR, March 4, 2007
DeLander G, Zweber A, and Kuntz T. Pharmacy Program Student Outcomes Assessment: Utility for curricular assessment and student self-evaluation. NABP Annual Meeting, Portland, OR May 20, 2007
Professional and Public Service:
Angela Austin-Haney, Director of Student Services and Head Advisor
• Elected Secretary for the Northwest Association of Student Affairs Professionals (NWASAP)
• Completed her term as Chair-elect for the Academic Advising Council (AAC) this past year and will be Chair for the 07-08 year.
Dr. John Block
• attended the winter meeting of the National Association of Boards of Pharmacy’s Foreign Pharmacy Graduate Equivalency Examination Committee in Austin, TX February 9-11, 2007.
• participated as the senior Medicinal Chemist in the August meeting of the National Association of Boards of Pharmacy's Foreign Pharmacy Graduate Equivalency Examination Review Committee in Mt. Prospect, IL; and participated as a facilitator at the March item writers workshop.
Zhengrong Cui was invited by the American Association of Colleges of Pharmacy to act as a grant reviewer for the New Investigator Program (AACP NIP), Pharmaceutics.
Gary DeLander
• President of the Rho Chi national pharmacy honorary society.
• Member, the Pharmacy College Application Service (PharmCAS) National Advisory Panel for the American Associaotn of Colelges of Phjarmacy (AACP)
• Site reviewer to the University of Wyoming for the Accrediitaiotn Council of Pharmacy Eduction
Theresa Filtz participated as grant reviewer for the National American Heart Association, and Secretary/Treasurer of the Molecular Pharmacology division of the American Society for Pharmacology and Experimental Therapeutics.
Arup Indra gave a seminar presentation entitled “Signal Transduction in Cancer” on June 27, 2007, to High School Science Teachers at OSU attending a Workshop called “Advances in Biotechnology: Human health and Gene Expression”.
Matt Ito
• Appointed as a board member of the Pacific Lipid Association which is the newest chapter of the National Lipid Association.
• Elected Treasurer of the Pacific Lipid Association for a term of 2 years.
• appointed to the Editorial Board of the Journal of Clinical Lipidology (an Elsevier publication).
• Appointed to the Credential Committee for the National Lipid Association. Their task is to develop applicant criteria and the exam for non-physicians to become Board Certified Clinical Lipidologists.
Wayne Kradjan
• Served as President elect, Oregon State Pharmacists Association
• Member of AACP Task Force on Recruitment and Retention of Faculty
Taifo Mahmud has been selected to be a member of the Editorial Board of Perspectives in Medicinal Chemistry.
Deanna Moretz
• elected Secretary for OSHP Board of Directors
• served as co-chair for the OSHP Educational Affairs Committee
Phil Proteau
• Chair of the Awards and Funds Committee at the American Society of Pharmacognosy Meeting in Arlington, VA, August 5-9, 2006.
• attended the Foreign Pharmacy Graduate Equivalency Examination Item Writing Workshop at the National Association of Boards of Pharmacy near Chicago, April 27-29.
Rosita Proteau served as Chair of the Education Committee and Chair of the Minority Initiatives Subcommittee of the Society of Toxicology and President of the Regional Pacific Northwest Association of Toxicologists.
Stacy Ramirez
• Appointed at the OSU Representative to the OSPA Board
• Launched her Pain Management clinic at Benton County Community Health Center (March)
• Elected Vice President of the Mid-Valley Housing Plus Board of Directors
Craig Williams. Accepted 2-year appointment as Associate Editor of Diabetes Forecast, a publication from the American Diabetes Association distributed to approximately 1 million diabetic patients in the United States every month.
Ann Zweber was elected president of the Oregon Board of Pharmacy at the last meeting, June 6, 2007.
Appendix E
Diversity Action Plan
College of Pharmacy
Sent as separate attachment
-----------------------
= Data Modified
= Unique Metric Data Needed
................
................
In order to avoid copyright disputes, this page is only a partial summary.
To fulfill the demand for quickly locating and searching documents.
It is intelligent file search solution for home and business.
Related download
- comparative health sciences faculty interest summaries 2020
- state of oregon project gutenberg
- carlson college of veterinary medicine oregon state
- functional and organizational analysis of the alabama
- oregon state university
- management seminar
- proposal title oregon state university
- department of administrative services budget and oregon
- oregonbuys agency category list home page
Related searches
- oregon state university online degrees
- oregon state university 2019 2020 calendar
- oregon state university 2020 calendar
- oregon state university masters programs
- oregon state university academic calendar
- oregon state university calendar 2021
- oregon state university start date
- oregon state university education department
- oregon state university start program
- oregon state university spring break
- oregon state university spring break 2021
- oregon state university term schedule